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Abstract           
MS is a disorder of the central nervous system, manifesting as acute focal 
inflammatory demyelination and axonal loss, and culminating with chronic multifocal 
sclerotic plaques. MS involves several nervous functional systems resulting in 
disability, has a rather unpredictable course, and thus leads to poorer quality of life. It 
is a disorder of young adults, and the most common cause of non post-traumatic 
neurological disability. It is believed to be caused by interplay between genes and the 
environment. Potentially any environmental agent can have a role in determining MS 
in susceptible populations and yet be neither a necessary nor a sufficient cause. 
Potential risk factors have been investigated, such as infectious agents, vaccines, 
stress, occupation, climate and nutrition. At what age in a genetically predisposed 
individual’s life, exogenous factors can interact to initiate MS is rather controversial, 
although this probably occurs within the first 15 years of life.  
The present work involves two broad areas in MS research: (i) epidemiological 
descriptive studies aimed at disclosing clues to disease etiology and mechanisms of 
disease induction, and (ii) the study of determinants of health-related quality of life in 
the MS population at large. 
The specific objectives to this work were: to disclose MS variation at a 
microgeographic level, as a possible expression of the spatial distribution of disease 
risk factor(s) (Paper I); to update and characterise MS incidence patterns, as a possible 
expression of temporal distribution of disease risk factor(s) (Paper II); to assess 
whether individuals that later develop MS have shared the same environment at the 
same age indicating common exposure to disease factor(s), and if so at what age has 
this occurred (Paper III); and to compare the self-perceived health status to the general 
population, with special regards to physical functioning, in MS patients with no or 
mild disability as objectively measured (Paper IV). 
All these studies have been conducted on the province of Sassari, northern Sardinia, 
insular Italy (450,000 pop. circa) based on a registry system of MS cases. 
 xi 
Epidemiological studies conducted over the past two decades using repeated 
assessments have shown that Sardinia is at high risk for MS with a prevalence of 150 
per 100,000 and an annual mean incidence of 6 per 100,000. To investigate the 
distribution of MS in Sardinia at microgeographic level a spatial analysis of the 
disease prevalence in the study area for year 1997 was conducted (Paper I). To 
overcome random variability due to small numbers of cases per geographic unit, a 
hierarchical Bayesian approach was adopted. Spatial clustering patterns in the 
province south-west and a west-to-east gradient were observed. 
An incidence study was performed on 689 MS patients with disease onset between 
1965 and 1999 in the study area (Paper II). The mean annual incidence rate increased 
significantly from 1 per 100,000 pop in 1965–69 to 6 in 1995–99, with no differences 
for gender and province sub-areas. The mean age at onset increased significantly 
during the same period from 25.7 to 30.6 years, while the proportion of patients with 
progressive initial course declined over time.  
Space-time cluster analysis was performed in the study area to indicate a possible 
shared exposure to MS risk(s) factors during the disease latent period, and the 
individuals’ age for this susceptibility period (Paper III). Residence changes from birth 
to clinical onset were recorded for all MS patients with clinical onset between 1965 
and 1999 in the study area. Closeness in space and time was defined as living in the 
same commune, at the same time and at the same age differing only by 1, 2 or 5 years. 
The analysis was performed from birth until age 25 years or disease clinical onset, and 
by demographic and clinical subgroups. Clustering was substantial in early childhood. 
It was most marked in the most recent cases, among women and in patients with 
relapsing-remitting course. No clustering was found when closeness in time was 
defined as a fixed number of years before onset, arguing against a fixed latency period 
of the disease.  
MS heterogeneous spatial distribution at microgeographic level, its increased 
incidence and change of clinico-demographic phenotypes over a relatively short period 
of time, and evidences of clustering in space and time in early childhood especially 
 xii 
occurring recently, are suggestive for the action of an exogenous factor(s) in 
determining MS. Ecological and case-control studies need to be designed and 
implemented to validate and characterise these observations. 
The self-perceived health status among MS patients with no or mild disability 
according to EDSS and the impact of self-rated physical functioning have been 
compared between a sample of fully ambulatory (EDSS 3.5) MS patients and the 
general population (Paper IV). SF-36 was used to self-rate health status. The 197 MS 
patients analysed (150 women and 47 men) had significantly lower mean SF-36 scores 
than the general population, except for bodily pain. Similar results were found for a 
sub sample of 107 patients (81 women and 26 men) with even lower disability (EDSS 
2.0). EDSS correlated weakly with the physical functioning subscale, explaining only 
2% of the variance in such SF-36 subscale. The regression of the physical functioning 
subscale on the other seven SF-36 subscales was significantly lower among MS 
patients than in the general population for all subscales, except for role limitation due 
to physical health problems and social functioning. Therefore factors other than 
physical functioning contribute to the low scores for the other dimensions compared 
with the general population. Neither disease course nor duration correlated 
significantly with SF-36 subscales. Strategies targeting a broad spectrum of health 
related issues for MS patients should be implemented starting already in the disease 
early stage. For cost-of-illness studies these findings provide clues to indicators to the 
disease socio-economic burden in the early stages, and elements for disease-specific 
interventions. 
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1. INTRODUCTION 
1.1. Multiple sclerosis  
Multiple sclerosis (MS) took centre stage in the 1860s when clinical neurology began 
to flourish. By the beginning of the 20th century, MS had become one of the most 
common reasons for admission to a neurological ward. Now, MS is recognised 
throughout the world, with around 2.5 million affected individuals,1 accounting for an 
estimated annual average expenditure of euro 24,183 per case and euro 1,159 million 
overall in Europe.2,3  
From a pathological perspective, MS is a disorder of the central nervous system, 
manifesting as acute focal inflammatory demyelination and axonal loss with some 
remyelination. This process culminates with the chronic multifocal sclerotic plaques 
hence the disease name. From a clinical perspective, MS involves several nervous 
functional systems and has a rather unpredictable course. It is a disorder of young 
adults, and the most common cause of non post-traumatic neurological disability. 
Diagnosis is based on clinical and paraclinical evidence of spatial and temporal 
dissemination, i.e., for at least two demyelinating lesions, affecting different sites 
within the brain or spinal cord, separated in time. MS is the prototype inflammatory 
autoimmune or immuno-mediated disease of the central nervous system for which 
some knowledge on basic etiopathogenetic mechanisms exists, that has allowed the 
implementation of strategies for treatment.  
The principal target of the immune attack in MS is the oligodendrocyte, the cell 
responsible for synthesising and maintaining the myelin sheath of about 40 adjacent 
nerve axons in the central nervous system. Myelin is a membrane wrapped around 
axons to form the insulating segmented sheath needed for saltatory axonal 
conduction. Voltage-gated sodium channels are located at the unmyelinated nodes of 
Ranvier, between myelin segments, from where the action potential is propagated and 
spreads passively down the myelinated nerve segment to trigger another action 
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potential at the next node. Demyelination interferes with nerve conduction to 
different extent from decreased velocity to its block. Paroxysmal symptoms, such as 
trigeminal neuralgia, ataxia, and dysarthria result from demyelinated axons which can 
discharge spontaneously and show increased mechanical sensitivity, or ephaptic 
transmission (cross-talk) between neighbouring demyelinated axons.  
The symptoms and signs of MS reflect the functional anatomy of impaired saltatory 
conduction at affected sites.4 The cerebrum is almost always involved as shown with 
magnetic resonance imaging (MRI), even though most white matter lesions cannot be 
linked to specific events or clinical symptoms. During the disease course, 
involvement of the visual pathway, with special regards to optic nerves, is 
encountered in up to 92% of patients. Lesions of the brain stem and cerebellar 
pathways produce precise clinico-pathological syndromes in over 50% of patients, 
usually characterised by abnormal oculomotion, incoordination of limbs, bulbar, and 
axial musculature. The spinal cord is affected in nearly 75% of patients, leading to 
alterations in motor, sensory, and autonomic functions. More vague symptoms, such 
as fatigue and mood disorders, are experienced by over 75% of patients, resulting in 
disability and poorer quality of life. 
1.1.1. Etiopathogenesis  
MS is almost uninanimously believed to be caused by interplay between genes and 
the environment. Ethnic groups resistant to MS living in areas at high risk for MS 
demonstrate that genetics is important in shaping overall population susceptibility.5,6  
Genetic factors 
MS is a genetic complex trait. Few or multiple genes are believed to interplay 
independently or interactively with non-heritable exogenous agents and start MS. 
Familial aggregation per se can have both genetic and exogenous causes. Aimed at 
testing genetic hypotheses, the pattern of familial occurrence has been extensively 
investigated. The change in the recurrence risk ratio in families of individuals with 
MS shows that first-, second- and third-degree relatives are more likely to develop 
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MS than the general population, and according to the degree of biological 
relatedness.7,8 The steep drop in rates observed between monozygotic twins (30.8%) 
and first-degree relatives (3.46%), and the further, yet less dramatic declines between 
first- and second-degree relatives and second- and third-degree relatives favours 
oligogenic or polygenic inheritance with epistatic interactions among susceptibility 
loci.8  
In a Canadian series of patients with half siblings, the risk among full siblings was 
3.11% as compared to 1.89% among half siblings9 and the rate of MS among first-
degree relatives of MS patients that had been adopted in early infancy was similar to 
that of the background population.10 Nevertheless, a risk gradient was observed 
between dizygotic twins (4.7%) and full siblings (3.46%), which cannot be explained 
fully on a genetic basis, since both groups share the same proportion of genome 
(50%) with the index case.  
Factors contributing to an increased familial risk for MS include gender, age at onset 
and affected relatives/parents. Based on the Canadian Collaborative Project on 
Genetic Susceptibility to MS (CCPGSMS) the risk of developing MS is 2-fold higher 
among the sisters of index cases as among brothers.11 The risk is nearly 2-fold among 
maternal than paternal half siblings, suggesting a maternal parent-of-origin effect.9 
Index cases with age at onset lower than 30 years,11 or with one parent with MS12 
were also associated to higher risk in siblings. A study on consanguineous matings 
showed that the risk was nearly 4-fold higher in siblings of MS patients with related 
grandparents versus that in siblings with unrelated ancestors.13 The CCPGSMS study 
on conjugal MS showed a risk of 30.5%, similar to that of monozygotic twins in 
Canada and higher than that of 2.7% among the offspring of matings with only one 
parent having MS.14  
The study of conjugal MS can also help determine whether there are factors 
(exogenous) that may facilitate MS transmission in adulthood. Despite concern about 
the available small sample sizes, and the role of recall bias, population-based studies 
on conjugal MS conducted on Canadian and Danish populations have shown that 
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recurrence rate within these matings does not differ significantly with that in the 
general population.14,15 Such evidence, which is used to point to genetically based 
determinants of MS, argues against an exogenous type of transmission, but only with 
regards to adulthood, and it is not informative to rule out the action of exogenous 
agents before disease onset. 
Population-based studies on twins have been a classical approach for investigating 
the relative roles of genes and exogenous exposure in determining MS. The studies 
on twins indicate that genes are involved in the process of susceptibility, but also that 
they cannot fully explain a partial concordance, for which environmental factors are 
likely to be responsible.  
Environmental risk factors 
Reviews on the role of environmental factors16-21 in MS etiology highlight the 
complexity in identifying proper specific design approaches and in interpreting the 
findings obtained. Potentially any environmental agent can have a role in determining 
MS in susceptible populations and yet be neither a necessary nor a sufficient cause. 
Potential risk factors investigated have been infectious disorders, vaccines, stress, 
occupation, climate and nutrition.  
Many groups have searched for bacteria and viruses in clinical samples of MS 
patients, but confirmatory evidence from independent laboratories has not yet been 
reached.22,23  
Patients with MS are seropositive for Epstein Barr Virus (EBV), and the titres of 
virus-specific antibodies are higher in individuals with the disease than in controls.24 
The difference in the seroprevalence rate is even more prominent in children with the 
disease (83% vs 42% in age-matched healthy individuals).25 Until now, however, no 
data unequivocally lend support to a direct role of EBV in the development of the 
disease, and in which pathways EBV plays a part in the pathogenesis of the disease is 
not clear. In pediatric MS no differences in seropositivity for most viruses between 
MS patients and controls has been found except EBV infection, and mumps and 
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measles after 15 years of age. A nested case–control design within the Nurses Health 
Study cohort26 aimed at investigating the serological association between Chlamydia 
Pneumoniae (CP) infection and the development of MS showed that the presence of 
CP-specific immunoglobulin G antibodies was associated with both an increased risk 
of developing the disease and a progressive course. The Human Herpes Virus 6 
(HHV-6) has also been hypothesised to be a candidate as infectious agent in MS, 
based on a significant increase in detected early antigens and on a correlation with 
exacerbations and onset.  
Although modern vaccines do not contain neural tissue derivatives, homologies can 
exist between microbial and neural epitopes that can stimulate the immune system 
and activate autoreactive clones.27 With this respect, it is reasonable to consider a role 
of vaccination in triggering both the disease ex novo, or new relapses. A number of 
studies, including case-controls designs, have been conducted aimed at finding 
associations between vaccination and onset of MS, optic neuritis, or relapse. The 
focus was particularly on influenza, hepatitis B virus, tetanus, measles, mumps and 
rubella. Confavreux and Compston27 in a recent review conclude that there is no 
association with an increased risk of developing MS or optic neuritis, and that 
vaccinations are not a risk factor for MS. 
Among occupational exposures, organic solvents have raised most concern in studies 
of MS causation. Odds ratios varying from 0.8 to 4.0 are reported from various case–
control studies, but statistical significance is almost never reached. Several 
methodological issues have been raised, such as the cross-sectional nature of such 
studies based on prevalence, self-reported exposure assessment reflecting recall bias, 
the lack of adjustment to confounders and the small sample sizes. Few studies have 
focused on the putative period elapsing between exposure and onset as well as 
defining ‘exposed’ by the necessary duration of exposure. The results from cohort 
studies are also controversial. 
Sun exposure, ultraviolet (UV) radiation and latitude are inversely correlated with 
MS. As MS has been reported to vary with latitude, a role of UV radiation has been 
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hypothesised, also based on the biological effects of UV radiation suppressing T-cell 
function. Ecological studies have shown a strong inverse correlation between UV 
radiation and MS and between residential and occupational exposure to sunlight and 
MS mortality, and showed that the incidence of skin cancer in the MS population was 
significantly lower than expected. However, other case–control studies found no 
association. Higher vitamin D intake was associated with a lower risk of MS. Due to 
confounding related to dietary factors and inconsistent measurements of sunlight 
exposure, the evidence is too weak to even partly explain the geographical variation 
in MS risk as an effect of sunlight. 
A causative role of traumatic brain injuries due to disruption of the blood-brain 
barrier has been suggested. Physical trauma (especially head trauma) has, however, 
not been found to be associated with MS onset, exacerbation or progression. On the 
other hand, compared with controls, people with MS had more frequently undergone 
intense mental stress or severely threatening life events a few years before onset. 
However, these studies have limitations related to inconsistent measurements of 
exposure, recall bias, small sample sizes and confounding. 
As MS is increasingly predominant in women, sex hormones have been hypothesised 
to play a causative role for their impact on the immune system. Epidemiological 
studies on sex hormones and MS have focused on four major risk factors: age at 
menarche, pregnancy, parity and use of oral contraceptives. None has provided 
sufficient evidence on the role of these hormones in causing MS. Whether pregnancy 
is associated with fewer relapses and postpartum with more is still debated. 
Diet as a risk factor has been of interest in MS studies for over 50 years because it 
implies potentially toxic agents and because it varies with ethnicity and geographical 
areas in which MS occurrence also differs. Because most studies are cross-sectional, 
the role of nutrition in causing MS is inferred from observations on individuals’ 
current nutritional status. Several population-based ecological studies conducted in 
different areas reported that MS is correlated with the consumption of milk, dairy 
products, meat and especially animal fat but few case–control studies have confirmed 
 
 
7 
this. Dietary fat has been reported to correlate with MS and mortality and fatty acids 
reported to have a role in the MS course. Lower levels of linoleic acid, an omega-6 
fatty acid, have been found in the blood, cerebro-spinal fluid (CSF) and brain of MS 
patients, but the interpretation of such findings is controversial. Other dietary factors 
such as brain, sweets and confectionery, new potatoes, alcohol, smoked meat 
products, pasta, bread, horsemeat, coffee, tea and breast milk have been investigated 
as potential risk factors in MS. Vitamin B12 deficiency is not unusual in MS patients, 
but no evidence indicates its causative role. No consistent data from analytical studies 
and clinical trials confirm any relationship between MS and nutrition. 
Methodological problems in these studies include selection bias, recall bias in 
patients as compared to controls and within patients before and after diagnosis, the 
lack of objective measurements of dietary factors and the scarce control for possible 
confounders, such as socio-economic class. 
Results from case–control and cohort studies indicate that cigarette smoking is a risk 
factor for MS. The risk of developing MS was almost 2-fold among smokers as 
compared to never-smokers in a Norwegian population.28  
Lastly, an excess of spring births has been detected for MS patients.29,30 Pooled 
analysis of datasets from Canada, Great Britain, Denmark and Sweden (n = 42,045) 
showed that significantly more people with MS were born in May (9.1%) and 
significantly fewer were born in November (8.5%). This represents a 19% decreased 
risk of MS for those born in November compared with those born in May. The 
association between month of birth and risk of MS,29 seasonal variation and risk of 
MS onset, or disease activity31 has been interpreted as a climate-related interaction 
between genes and environment during gestation or shortly after birth, at least in 
northern Caucasian populations. Methodological issues such as random variation, 
misclassification and statistical methods applied, however, may partly explain such 
results.31 
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1.2. The latent period 
The question arises as to at what age in a genetically predisposed individual’s life, 
exogenous factors can interact to initiate MS.  
The manifestation of the first symptom(s) or sign(s) eventually attributed to MS32 is 
referred to as the clinical onset of MS, and the age at onset is therefore the age at 
which such clinical manifestations occur. However, biological initiation of MS does 
not coincide with the clinical initiation, and the disease process is believed to start 
earlier in life.  
Attempts have been made to conceptualise a disease etiologic process into a sequence 
of fixed events that could reflect the action of risk factors.33 The time elapsing 
between disease initiation (induction) and clinical onset is referred to as the 
incubation period, specifically for infectious processes, and latent period otherwise. 
In disease etiology, however, not only such period simply represents the time lag 
between disease initiation and detection, but it may reflect part of the etiologic 
process itself, occurring subsequently to the action of the cause. This appears to apply 
to putatively multifactorial disorders, in which the initiating cause may not be 
sufficient, but necessary, and the action of further agents is needed for the disease to 
develop. The period between causation and disease initiation is defined induction 
period, which includes the time at which the earliest component causes influence the 
etiologic mechanism.33 Genetics is considered the most common earlier component 
cause. However, if we referred the induction period to the more specific component 
cause and not the earlier, any attempt at characterising the induction period would be 
more informative and useful. Therefore, the induction period varies also in relation to 
what we mean for cause. The latent period could virtually be null if diagnostic tests 
were able to detect the presymptomatic disease.33 Practically as the precise point in 
time at which disease is initiated is not detectable, the latent period is included in the 
induction period, and the two cannot be empirically separated. Then, the interval 
from etiologic action to disease detection is referred to as the empirical induction 
period. A lengthy empirical induction period increases the possibility for 
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confounding and attenuates the association between cause and disease. Subsequently, 
in etiological research based on case-control studies, dilution of the effect of a 
putative factor occurs when a relevant exposure is considered to have acted outside 
the time span corresponding to the empirical induction period. The attenuation of the 
effect-estimate leads to nondifferential misclassification, due to a bias which obscures 
the real effects and generates conflicting results among studies differently designed. 
In case-control studies, lifetime exposures histories will underestimate an effect 
which pertains to exposure at a specific time before disease. Methodological 
approaches aimed at narrowing such interval window using different assumptions 
(e.g., the induction period varies from 5-10 years, or 10-15 years etc) will help to 
locate the greater effect in time without misclassification bias. Cases will be 
considered only individuals with onset after the defined empirical induction period. 
In cohort studies, using the different exposure assumptions, the highest incidence rate 
of a disease will reflect the most likely length of the induction period for that disease. 
In case-control studies, only cases with the defined time of putative exposure will be 
included.  
When does the induction period begin if the exposure is chronic? In this case, it 
might require years before the exposure becomes relevant in determining the disease. 
Methodological approaches to obtain estimates of such exposures are based on the 
assumption that such interval could reflect a time-dependent process, or a cumulative 
dose effect defined by either time since first exposure, or a function of time and dose 
rate.33 
In MS research the term susceptibility period is often encountered in literature in 
relation to the time or age of exposure to the putative risk factor(s) and within the 
empirical induction period. The susceptibility period can therefore be viewed as an 
attempt to disclose the disease “induction” period and therefore clues to its etiology. 
According to Poser, the susceptibility period consists of the development of the ‘MS 
trait’, a systemic, non-pathological condition which does not involve the nervous 
system parenchyma, and that may develop in some individuals who are genetically 
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susceptible to MS.34,35 He defines such condition as the ‘premorbid stage of MS’. In 
principle, this is analogous to the sickle-cell trait, or glucose-6-phosphate 
dehydrogenase deficiency in that it requires a trigger to develop into the overt disease 
MS, such as a ‘disease waiting to happen’, which differs from an asymptomatic 
condition of MS because no lesions of myelin or axons can be detectable. Poser 
believes that the MS trait does not necessarily affect all MS-susceptible persons, and 
that not all persons with the MS trait will eventually develop MS. The MS trait is 
characterised by an immunological hyperreactivity with an exaggerated response to 
viral antigens, the presence of oligoclonal bands in the cerebrospinal fluid – a non-
specific sign unrelated to activity in the overt disease itself - and an increased 
vulnerability of the blood-brain barrier, likely the primary event in the disease 
pathogenesis.36 As the MS trait is completely asymptomatic and is not even 
associated to MRI changes, it is not possible to determine at which age it develops. It 
is hypothesised that it occurs prior to puberty, the age of putative biological onset, as 
a manifestation of a localized immune response to a variety of non-specific antigenic 
challenges, most likely viral. In order to develop into MS, it is necessary that 
immunoactive substances penetrate into the central nervous system after a second and 
more specific antigenic challenge on the blood vessel wall adhesion molecules. Also, 
other mechanisms have been suggested such as trauma, electrical injury, and lipid 
solvents. 
Despite the potential of epidemiological studies for investigating MS empirical 
induction period, and more specifically, for identifying and characterising its 
susceptibility period, few such studies are reported in literature. Among the designs 
used are migration and cluster studies, including the analysis of epidemics, and 
statistical models.37  
Migration studies are aimed at comparing the incidence of MS in migrants from 
countries with high risk to those with low risk, or viceversa. Ultimately, they help 
determine whether the disease initiation is predominantly driven by genetically 
determined mechanisms, or by the different distribution of environmental factors as 
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across geographic regions. Relevant studies include those conducted among 
immigrants from Europe to South Africa and in the population born in South 
Africa.38,39 Age-adjusted prevalence and incidence rates were highest in European 
immigrants, lower in South African English and Afrikaners and lowest among 
admixed black and Caucasian Africans. The risk of MS was higher among the 
children of immigrants to the United Kingdom from India, Africa and the Caribbean 
than among their parents, and it was similar to that among children born in the United 
Kingdom.40 In France, the risk of MS was higher among people with Vietnamese 
mothers who had migrated from Vietnam at age 20 years or younger.41 These 
individuals, however, were likely to have admixed genes from French fathers. 
The prevalence of MS was 7 among Japanese living in Hawaii, 10.5 among native 
Hawaiians and 34 among migrant populations from North America42 largely 
reflecting the rates of Japanese and Caucasians living in California and in Japan.43 
Age of migration is crucial in determining the risk. Adult European immigrants to 
South Africa had a 3-fold higher risk for MS than those migrating at age 15 years or 
younger.44 In a study conducted on Ashkenazi (from northern Europe) and Sephardic 
Jews (from Asia and Africa) in Israel, the risk was higher in the Ashkenazis in 
relation to the older age at migration (after adolescence).45 These evidences suggest 
that age effect is probably related to the first two decades of life. 
Conversely, a study on prevalence in a migrant population from the United Kingdom 
and Ireland to different regions in Australia showed that the risk among individuals 
who migrated before age 15 years to low-risk areas in Australia did not differ from 
that among individuals migrating at age 15 years or older, suggesting that 
environmental factors may operate over a longer period of time after childhood.46 
The validity of migration studies is undermined by methodological issues, such as 
small sample sizes, the difficulty of identifying a denominator for the migrant target 
population, the age of MS onset relatively to that of migration, selection bias and 
confounding based on socio-demographic features such as age, gender proportion, 
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health status and reasons for migration.37,47 Further, too few studies have been 
conducted on MS incidence among migrants from low- to high-risk areas,37 and 
relevant secular changes in the prevalence within the general population over time 
can mask prevalence in subgroups. 
Cluster studies represent a further approach to investigate MS initiation and 
susceptibility. Epidemics are a special case of clusters of case in space and time with 
a shorter and better defined latency period and are ideally more successful for 
characterising the susceptibility period. The most comprehensive report on MS 
epidemics is Kurtzke’s 30-year observational study on the pattern of MS in the Faroe 
Islands in the North Atlantic, where in 1998 MS prevalence rate was 66 per 
100,000.48 The first MS case among Faroese native residents since 1900 was reported 
in 1943. Based on the analysis of patterns of MS occurrence and patients’ residence 
history, MS was hypothesised to be acquired at least 2 years after exposure to an 
exogenous factor and during puberty (age 11 years). After the first case, 21 new cases 
developed MS in a type 1 epidemic (occurrence due to initial exposure to an 
exogenous ‘virulent’ factor in a susceptible population virgin to that specific 
exposure). The source of such exposure was believed to be a widespread, specific, 
persistent infectious yet unknown agent introduced by the British troops occupying 
the Faroe Islands during World War II. The consequent asymptomatic infection, the 
‘primary MS affection’, would convert into clinically detectable MS years later and 
only in subsets of individuals. Susceptibility to the primary MS affection would be 
limited to age 11–45 years at the start of exposure, whereas the primary MS affection 
would be transmitted at age 13–26 years and before clinical onset. The first epidemic 
was followed by three successive epidemics of 10, 10 and 13 cases, respectively, 
defined by calendar time and age of exposure, with peaks at 13-year intervals.48 This 
led to conclude that MS was the result of a specific transmissible infection from 
person to person. After reanalysing the data, Cooke49 critiqued the ‘pubertal 
hypothesis’ with a ‘protective hypothesis’, arguing that the pubertal exposure 
consisted of a childhood infection with later onset, and that early childhood would 
instead be the true MS induction period. Methodological issues were raised against 
 
 
13 
the evidence of MS epidemics due to small sample sizes, multiple assessments over 
time based on registries, the use of old and more inclusive diagnostic criteria and the 
plausibility of the role of the British troops in determining the epidemic.50 
In the Orkney and Shetland Islands, MS prevalence rates steadily increased by almost 
three-fold to 110 in the Orkneys and from 134 to 184 in the Shetlands between 1954 
and 1974. Over the same time period, however, general awareness of MS improved.51 
Incidence rates were stable in 1930–69, but a slight reduction at the end of the period 
was attributed to underascertainment and to more stringent diagnostic criteria. 
In 1979, incidence in Iceland was studied based on the 168 MS cases retrospectively 
ascertained since 1900.52 Until 1922, MS cases had been sporadic. The mean annual 
incidence rate was 1.6 in 1923–44 and 3.2 in 1945–54, followed by plateau and a 
decline to 1.9 in 1955–74. The age at onset also increased from 1945–49 to 1950–54. 
This whole incidence pattern was interpreted as a postwar epidemic of MS. This 
trend was reanalysed53 and explained by improved diagnostic accuracy due to the 
increased number of neurologists in the 1930s and in the 1970s and easier access to 
neurological care.  
Space-time cluster analysis is used to test a single source exposure, usually an 
infectious agent, and the time, space or age of putative susceptibility to such 
exposure. The idea behind this analysis is that if the number of observed cases that 
have been close in time and space is significantly higher than expected just by 
chance, then the pattern suggests an infectious disease spreading from case to case.54 
A detailed description of methodology and limitations is given in Section 1.4.3. 
Pre-onset natural history statistical models have been built by Wolfson et al55 to 
estimate the distribution of the disease entire latent period. In this model all the 
patients were assumed to have acquired the disease after a fixed time period, i.e., the 
susceptibility period. Several such periods previously reported in the literature were 
accounted for in the model, however the most likely one was found at 10-15 years of 
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age and the latent period estimated duration was 18 years. Similar findings were 
obtained in a dataset of French MS patients.56 
1.3. Descriptive epidemiology of MS: general overview  
The geography of MS and its variation over time have been systematically 
investigated for the past 70 years6,19 (Figure 1).  
 
Figure 1. The MS prevalence worldwide (per 100 000 population) 
 
Reproduced from Marrie19 with permission of Elsevier, Ltd. 
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Despite the wealth of publications dealing with occurrence of MS throughout the 
world, any attempt to define the geography of MS remains as difficult as ever. An 
increase in the disease occurrence is reported almost worldwide, and 
exogenous/environmental factors have been hypothesised to account for such change. 
However, the geographical distribution of absolute rates might depend on the 
distribution of genetic susceptibility alleles and their interaction with environment. 
Environmental and genetic determinants are not mutually exclusive, and the nature-
versus-nurture controversy is a hot debate in MS epidemiology today. Ethnicity and 
ancestry are often used to refer to populations’ genetic origin but they can also refer 
to cultural habits and lifestyle factors, and confound results. 
A summary of MS incidence rates from population-based studies conducted in 
Europe on samples of 50,000 and larger, is reported in Table 1.  
 
 
16 
Table 1. Incidence (per 100 000 population per year) of MS in European 
countries 
Country Time 
interval 
Study 
pop. size 
Rate 
(95% CIs) 
Albania 1968–1987 3 091 000 0.5 (0.4–0.6) 
Croatia (northern Adriatic islands) 1956–1998 50 552 1.3 (–) 
Croatia (Osijek-Baranya) 1991–1998 298 600 3.5 (–) 
Denmark 1980–1989 nationwide 5.0 (4.8–5.2) 
Finland (Seinäjoki) 1979–1993 197 000 11.6 (10.1–13.1)a 
Finland (Uusimaa) 1979–1993 1 278 000 5.1 (4.1–6.3)a 
Finland (Vaasa) 1979–1993 179 000 5.2 (4.8–5.5)a 
Finland (central) 1994–1998 263 886  9.2 (7.4–10.9) 
France 1993–1997 94 000 4.3 (2.9–7.2) 
Germany (Lauer, personal data) 1979–1992 100 000 4.2 (–) 
Greece (Evros) 1994–1999 143 000  2.4 (1.4–3.7) 
Hungary 1997–1998 400 128 5.5 (–) 
Iceland 1991–1995 255 000  0–5 (–) 
Ireland (Donegal County) 2001 129 994 5.1 (1.6–11.7) 
Ireland (Wexford County) 2001 104 372 4.5 (0.3–8.7) 
Italy (Ferrara, north) 1990–1993 368 000 2.4 (1.6–3.4) 
Italy (Sicily, insular) 1990–1994 338 000 3.9 (3.0–5.0) 
Italy (Sardinia, insular) 1995–1999 454 000 6.1 (5.1–7.2) 
Italy (Padua, north) 1995–1999 820 000 4.2 (3.7–4.7) 
Malta 1989–1998 400 000 0.8 (–) 
Netherlands (Groningen) 1985–1990 560 000 3.0 (–) 
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Norway (Hordaland County) 1978-1982 405,063 5.0 (-)b 
Norway (Hordaland County) 1993-1997 441,660 6.0 (5.0–7.2) 
Norway (Hordaland County) 1998-2002 441,660 3.0 (2.3–3.8) 
Norway (Møre and Romsdal County) 1975-1979 237,278 3.8 (-) 
Norway (Vestfold) 1978-1982 188,664 2.4 (-) 
Norway (Nord-Trøndelag County) 1974–1998 127 000 5.3 (3.7–7.5) 
Norway (Oslo) 1992–1996 484 000 8.7 (6.3–11.9)a 
Norway (Troms and Finnmark 
Counties) 
1989–1992 225 000 4.3 (3.0–5.9) 
Poland (west) 1993–1995 50 000 2.2 (–) 
Romania (Mures County) 1976–1986 600 000  0.9 (–)a 
Russian Federation (Iaroslavl) 1996–2001 – 3.0 (–) 
Slovenia 1990s  2.9 (–) 
Spain (Mostoles, central) 1994–1998 196 000 3.8 (2.7–5.3) 
Spain (Teruel, east) 1992–1996 143 000 2.2 (–) 
Sweden (Västerbotten County) 1988–1997 256 000 5.2 (4.4–6.2) 
Switzerland (Canton of Berne) 1961–1980 920 000 4.0 (3.7–4.3) 
The former Yugoslav Republic of 
Macedonia 
1990s – 0.2–1.2 (–) 
Ukraine (Vinnytsya) 1990–1994 390 000  0.7 (–) 
United Kingdom (northern 
Cambridgeshire) 
1990–1995 379 000 4.8 (3.8–6.0) 
United Kingdom (southeastern 
Scotland) 
1992–1995 864 000 12.0 (10.6–13.3) 
a Only Poser Committee diagnostic criteria for definite MS 
b McAlpine diagnostic criteria 
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Whether the reported variation in disease rates over time partly reflect a true change 
in MS risk or merely improved case ascertainment, demographic factors, such as 
increased survival, or better study methods over time is still debated. The outlining of 
geographical patterns is undermined by the variation in the size, age structure and 
ethnicity of the populations surveyed, case ascertainment; the level of healthcare and 
expertise, degree of public awareness of MS and access to diagnostic procedures; and 
the methods applied to study designs and statistical analysis. Prevalence rates almost 
invariably increase with multiple-source repeated assessments over time and when 
small populations are used.6,21 
1.4. Investigating variability of disease distribution in space and time: general 
overview  
Epidemiological descriptive studies are of unquestionable importance in investigating 
the multifactorial etiology of rare diseases like MS. Although they only allow to 
describe the existing distribution of putative associated variables without regards to 
causal hypotheses,57 still they are the first approach to document the health of a 
population and yield working hypothesis to more rigorous and analytical studies.58 
Traditionally descriptive epidemiological studies focus on person, place and time, but 
they should also be able to answer five basic “W” questions – who has the disease, 
what is the disease under study, when is the disease common or rare, where does or 
does not the disease arise, why did the disease arise (clues for more sophisticated 
studies).58 
Among the descriptive studies are cross-sectional, or prevalence, studies describing 
the health of populations in terms of the distribution of exposure and outcome which 
are ascertained at the same time, hence the cross-sectional nature. These study are 
rather easy to undertake, but, due to their post-hoc nature, fail to provide clues on the 
temporal sequence (and thus to the disease etiology) of exposures and outcomes, with 
the exception of long-standing exposures, such as gender or blood type.  
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Surveillance is also a type of descriptive study. Surveillance consists in the “ongoing 
systematic collection, analysis and interpretation of health data essential to the 
planning, implementation and evaluation of public health practice, closely integrated 
with the timely dissemination of these data to those who need to know”.59 
Surveillance can be active, i.e. active search for cases, or passive, i.e., the data are 
already collected in traditional channels, such as death certificates.58 
1.4.1. Spatial cluster studies 
The estimation and presentation of spatial summary of health outcomes, such as 
prevalence rates of MS, has long characterised the history of epidemiology, and it is 
referred to as geographical analysis of health data or disease mapping.60-62 Disease 
mapping is aimed at providing a description of health outcomes, generating 
hypotheses, allocating health resources and assessing the variability in underlying 
disease exposures. Mapping crude estimates is especially difficult for rare diseases 
and small areas, such as it is the case for MS prevalence by administrative 
communes. In this scenario, disease mapping is biased by variability due to sampling 
or chance. Hierarchical models,61 among which is the Bayesian approach63,64 can be 
used to filter out (“smoothing”) the random variation from the estimated rates due to 
the small numbers. The Bayesian ecological model consists of a three-stage 
hierarchical model within which disease mapping data may be viewed. Health 
outcomes are usually available as area-level aggregated count data which therefore 
represent the basis for disease mapping. So we consider a study region A (e.g., a 
province), which can be divided into N small areas A1….AN (e.g., the communes). For 
a given set of areas, a set of observed cases O1….ON and corresponding denominators 
are obtained. The expected number of cases E1….EN in each area is calculated by 
indirect standardisation, and stratified by age, gender or other confounders, using a 
set of reference rates, so that the relative risk rather than the crude rate is used.60 We 
have thus obtained the standardised morbidity ratios (SMRs) expressing the ratio 
between observed (O) and expected (E) number of counts in an area (A). For rare 
diseases, the expected values can also be calculated by Poisson regression, and 
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assuming that ON are distributed according to Poisson distribution (λNEN), where λN 
is the relative risk for each area. The SMR ON/EN is then the maximum likelihood 
estimate (MLE) of λN.  
Mapping MLEs can however be misleading because of sampling variability that 
make estimates unstable, and also because of overdispersion or extra-binomial 
variation due to a possible inconstant disease risk distribution in the population.65  
The Bayesian hierarchical model allows dividing the extra-binomial variation into 
two components.66 The first component reflects our a priori belief in a simple 
spatially unstructured (and thus non measurable) extra-binomial variation which we 
refer to as heterogeneity. The second component reflects our a priori belief in a 
smooth variation across sub-areas and spatially structured, which we refer to as 
clustering. Explanatory variables can be also used in the model, which consist of 
measurable ecological variables known to be related to the disease risk.  
Heterogeneity is a random component whish is assumed to be normally distributed 
with the mean given by the overall mean, whereas clustering is assumed to be 
normally distributed with the mean given by the means of the neighbouring clustering 
estimates, i.e., of areas geographically adjacent from which they “borrow strength”. 
The variance distributions of the two extra-binomial variation components are 
distributed as a chi-square variable. The model is hierarchical in that a prior 
distribution has to be specified at two stages, heterogeneity and clustering. The true 
prevalence pi stems from a combination between the prior distribution including 
heterogeneity and clustering, with the information contained in the MLEs. The 
posterior distribution is so obtained. The analytical form of the desired posterior 
distribution can be obtained by generating samples using the Markov chain Monte 
Carlo technique.67 For each commune, the proportion of the posterior samples with a 
mean greater than the global posterior mean (i.e., the overall mean prevalence) can be 
computed, and it is referred to as the posterior probability (PP). The PP is the 
Bayesian equivalent of the p-value68 and can also be mapped to identify those areas 
wherein the risk is significantly higher or lower. The PP map can be interpreted as 
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follows: PP>0.90 strongly indicates that the area-specific risk is higher than the 
reference value, while PP<0.10 strongly indicates that the prevalence is lower. In 
those areas where PP falls in the intervals 0.75-0.90 and 0.10-0.25, only an indication 
that the risk is respectively higher or lower than the reference value is given. When 
the PP value falls in the central interval (0.25-0.75) no informative evidence is given.  
In this model, crucial is the choice of the prior distribution, as it yields an estimate 
which is a compromise between the area-specific prevalence and the reference value 
depending on the prior distribution. This allows to study local geographical variation 
of the disease, in contrast to broad-scale (e.g., national) comparisons. Extremes 
prevalence estimates are pulled towards the reference, the more consistently, the more 
unstable they are, and so this applies especially for areas with few cases. In this way 
the empirical map is smoothed and the spatial trends are more interpretable. The 
choice of the prior distribution (heterogeneity versus clustering) depends on our 
belief of how high or low the risk in the cluster will be as compared to the area at 
large. A clustering distribution is chosen if the risk in the cluster is expected to be 
higher than the area.  
Unstructured and structured variability can be combined into one statistical model, 
the convolution prior,69 to which they independently contribute. The third and final 
stage of the Bayesian approach is aimed at specifying a hyperprior for the parameters 
related to the unstructured and structured variability in stage two.61 This very 
theoretical statistical step is crucial in that it conditions the final disease mapping. 
The choice of the hyperprior is usually based on experience and sensitivity 
analyses.66,70 
1.4.2. Incidence studies 
Incidence is one of the basic measures of disease occurrence.71 It takes into accounts 
the number of individuals in a population that develop a disease, and also the length 
of time experienced by all persons during the risk period in that population. The 
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incidence rate is the number of new cases of diseases (incident number) divided by 
the person-time spent in the population.  
In chronic diseases with irreversible states, such as MS, the first occurrence of disease 
onset is the eligible event, and make up the numerator. The number of disease onsets 
in this case is also the number of people experiencing the event. In epidemiological 
studies of MS we deal with open populations, wherein individual contributions do not 
begin at the same time and the population is open to new members, who can enter 
through births, migration, etc., or exit through death, emigration, disease 
occurrence.71 These populations are usually at steady state, because the number of 
entering people is balanced by people exiting from the population, in terms of age 
and gender structure, and distribution of risk factors. There are various levels of 
definition for incidence, however, because the onset of MS is rare in the short time 
interval usually considered (within a year), the incidence proportion is what actually 
we refer to as incidence rate. 
Establishing the time (age or year) of onset of MS can be difficult but it is not 
impossible, as compared to other neurological conditions characterised by a slowlier 
and insidious onset, such as dementia or Parkinson’s disease.72 By means of 
collecting the patient’s history meticulously, it is possible to allocate in time 
individuals’ signs and symptoms attributable to an onset of MS.32  
The MS incidence in most high risk areas ranges from 1 to 10 per 100,000/year, and 
is most often computed retrospectively or by means of cross-sectional surveys, along 
with prevalence rates. Prospective incidence studies of MS are difficult to undertake 
as they require following up large population cohorts for long periods of time. 
However, registry and surveillance systems have now been established that will 
eventually overcome such difficulties. Among the most relevant such systems in 
Europe, are the Danish MS Registry (DMSR) and the Norwegian National MS 
Registry (NNMSR). The DMSR was started in 1948 and since then updated by 
prospectively and retrospectively recording information on MS incident cases from 
multiple sources.73 It has provided unselected patient samples for assessing the 
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disease natural history, familial risk and risk for comorbidity in both case-control and 
cohort studies, apart from multiple assessments of incidence, prevalence and 
survival.74-82 The NNMSR was established in 1998, and covers at the moment 
(autumn 2006) over 60% of the whole Norwegian population, with the western 
region (950,000 pop. ca) being almost thoroughly complete.83 The NNMSR includes 
a biobank unit for collection of cerebrospinal fluid and serum, DNA, and tissue 
samples.  
In most other settings, incidence data are obtained from defined geographic areas for 
which demographic data are available at specific time points (e.g., census data) and 
cases are actively and more or less systematically searched for in hospitals, outpatient 
clinics, individual physicians, health insurance organizations, MS societies, etc. 
Accurate case ascertainment is based on the probability that these patients are 
diagnosed and identified by the search which also depends on the degree of access to 
such sources.5 The diagnosis of MS in turn is influenced by the standards of medical 
care, level of disease awareness in the community and the sensitivity of the diagnostic 
criteria applied. Intuitively, if these are lacking, diagnosis is delayed and prevalence 
underestimated. Incidence can be underestimated only if cases will die before they 
are diagnosed. However, at least in multiply assessed populations and because of the 
nature of MS itself, this is quite unlikely and we may conclude that diagnostic delays 
only marginally affect incidence rates. Furthermore, because of the growing better 
quality of diagnostic facilities and awareness, the diagnostic delay has dramatically 
dropped from an average of 10 years to less than 1 year in the past 2 or 3 decades.  
To such shortening of time has also contributed the change in the diagnostic criteria. 
When the two most recent sets of diagnostic criteria, i.e., the Poser et al84 and the 
McDonald et al85 criteria, were applied to 76 patients seeking medical specialist care 
for suspected MS, MS was diagnosed more often according to the McDonald et al 
criteria than the Poser et al clinically definite criteria for MS (52% versus 38%).86 
Fast diagnoses may lead to a biased increase in the incidence. In fact, because of the 
retrospective nature of MS epidemiological studies, the need for comparing 
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epidemiological indices among different settings and the reduced interobserver 
variability, the Poser et al criteria are still the most commonly encountered 
classification in epidemiological surveys.87  
Not only factors biasing the numerator, but the choice of the denominator can 
obviously change incidence rates. With this respect, and given the possible different 
age- (most unlikely gender-) structure of the populations under study, age- (or 
gender-) adjustment to a common standard population is very important as it allows 
for comparisons and correct interpretations of the data.88 An example of such 
importance are the findings from a meta-analysis of population-based incidence and 
prevalence studies on MS from 1980 through 1998 in which rates were age- and 
gender-adjusted to the World and the European standard populations.89 When the 
mean crude and age- and gender-adjusted prevalence and age-adjusted incidence 
rates were stratified by latitude, the latitudinal gradient, which was highly significant 
for the crude rates, became less remarkable for the age- and gender-adjusted 
prevalence rates and not significant for the age-adjusted incidence rates.  
1.4.3. Space-time clustering studies 
Cluster studies are among the methodological approaches used when investigating 
disease initiation and its latent period (see Section 1.2.). A cluster of cases is defined 
as any departure from the random distribution of cases, either in time or space, or 
along any other axis.54 Two types of cluster analysis are most commonly used in 
epidemiology, i.e., the post hoc and the space-time cluster analysis. The former is 
driven by an excess of cases - most frequently only apparent -within small geographic 
areas, detected by patients, mass media and public opinion.54,90-92 It represents the 
basis for disease mapping (see Section 1.4.1.). The problems with post hoc cluster 
studies in determining the validity of such excesses of cases are linked with the 
cluster report itself, the determination of the number of cases and diagnostic 
accuracy, the population at risk, the definition of the study area (usually too small), of 
the study time (usually too short), biological plausibility up to the feasibility of an 
etiological study with usual small numbers. Ultimately, the crucial issue with post 
 
 
25 
hoc studies is to assess whether the observed cluster represents a real biological event 
or is simply due to a random increase in incidence.  
If post hoc cluster studies are motivated by observation, space-time cluster analysis is 
motivated by a hypothesis and should be conducted in populations with no (or little) 
previous evidence of cluster.54 This model is based on the study of time and place of 
residence during the putative acquisition period of a disease, so as for MS, from birth 
up to clinical onset. Space-time cluster analysis is therefore used to test a single 
source exposure, usually an infectious agent, and the time, space or age of putative 
susceptibility to such exposure. Several types of space-time cluster models can be 
used,93 all based on comparing the distance in time and space at disease onset or prior 
to it, among pairs of individuals. The idea behind this analysis is that if the number of 
observed cases that have been close in time and space is significantly higher than 
expected just by chance, then the pattern suggests an infectious disease spreading 
from case to case.54 Detailed information on patients’ changes of residence and 
relative calendar time are necessary for this analysis, which can only come from 
population-based registry systems or multiply assessed populations over time.  
A space-time clustering effect can also be searched in diseases with long latency such 
MS as an attempt to disclose “exposure aggregation”.37 Although likely masked by 
the aspecific multifactorial nature and the long and variable pre-onset history of the 
disease itself, they can provide relevant clues to exposures, time or age of disease 
acquisition and more susceptible individuals.  
1.5. The Sardinian population  
Sardinia lies between latitudes 38° 51’ 52” and 41° 15’ 42” N and longitudes 8° 8’ 
and 9° 50’ E from Greenwich.  
The Sardinian population originates from an early split in the Caucasoid group, and 
features a peculiar genetic asset which differs from that of other Caucasians or even 
mainland Italians.94 Sardinians’ origins in prehistory are not well known. However, 
historic, anthropologic, and genetic studies indicate that they are an ethnically 
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distinct, homogeneous group. The original inhabitants of the island withdrew from 
contacts with foreign populations who occupied the island coastal and plain areas in 
subsequent centuries, and settled in the mountainous interior areas of central Sardinia, 
mostly inaccessible to others. Successive waves of invasions by Phoenicians, 
Carthaginians, Romans, Vandals, Byzantines, Arabians, Ligurians, Tuscans, 
Spaniards, and Piedmontese failed to penetrate the wild inland, and especially today’s 
province of Nuoro and its core region Barbagia. Barbagia, the “region of the 
barbarians”, as the Romans called it, represents the core of preserved ethnic and 
genetic peculiarities among aboriginal Sardinians.94,95 Comparative studies on human 
leukocyte antigen (HLA) allelic frequencies have clearly demonstrated the genetic 
isolation of Sardinians from other Italian and European populations.96,97 The 
persistence of certain linguistic relics in the Sardinian language and the uniqueness of 
family names lend further support to their isolation.98 After World War II until 1980s, 
there was a consistent emigration from Sardinia to industrialized regions of northern 
Italy and Europe. Based on official data, the average annual emigration during this 
period was around 520 per 100,000 population. Later on, the migration flux was 
negligible (around 1.6%) and did not change substantially over time.  
The settlement of the city of Sassari, northern Sardinia, goes back to nearly 2,500 
years B.C., i.e., to the Nuragic era. Later, Sassari represented the hinterland to Turris 
Libyssonis (today’s Porto Torres), which was a very active colony and harbour in 
Roman times and until the seventh century. Sassari became an important urban centre 
between the seventh and eighth century, when the Saracen incursions gradually 
depopulated the coastal areas and the aboriginal population concentrated in the 
hinterland. A series of invasions followed:99 Sassari was ruled by the Pisans until 
1300 ca, Aragonese and Spanish until 1700 ca and Austrians until 1720 ca. In 1720 
Sardinia was granted to the King of Piedmont in exchange for Sicily and became part 
of the Savoy Kingdom. Despite the chain of conquests, Sardinians’ population 
structure did not change substantially. Except for few well identified foreign or 
mainland settlements on the coast, the gene flow into the aboriginal population had 
been quite limited.96 The genetic isolation of the Sardinians has been shown on the 
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basis of frequencies of genes implicated in determining blood groups,94 and their 
cultural isolation on the basis of the preservation of peculiar linguistic relics.100  
Based on geo-climatic features, four areas can be discerned within the province of 
Sassari: the coastal, the interior plain, the interior hill, and the interior mountainous 
areas. The coastal area is 15 Km broad and less than 200 m high, and has mild 
climate reflecting the alternating effect of land and sea breeze. The annual mean 
temperature is 16.5° (range 13.7°-20.5°). The interior plain area is over 15 Km 
distant from the coast with an altitude of 300 m or less, and an annual mean 
temperature of 15.9° (range 9.5°-23.7°). The interior hill area is comprised between 
300 and 600 m and can be further distinguished in a part closer to the coast, with 
milder climate, and an interior one wherein climate is close to continental. The annual 
mean temperature of these two sub-areas is 15.8° (range 12°-19.1°) and 13.5° (range 
9.2°-17.2°), respectively. The interior mountainous area, with altitude over 600 m, 
has mostly continental characteristics, with an annual mean temperature of 12° (range 
7.5°-16.7°). 
From a socio-economic perspective, the standard of living in Sassari is among the 
highest in Sardinia. The main occupations, i.e., commerce and tourism, expanded 
after 1950 as a result of improved air and sea connection with the Italian mainland 
and Europe. In the 1960s Sardinia became a readily accessible tourist attraction, with 
an increasing number of foreign tourists, mostly from northern European countries.  
According to local statistics on occupation, 27% of the province population is 
engaged in commerce, 21% in agriculture, 15% in building trade, 13% in services, 
11% in manufactory and energy production, 7% in hotel and restaurant industry, 4% 
in transportation, 1% in fishing and 1% in other occupations.101 Though nearly 30% 
lower than the overall European Union level, the employment rate in the province of 
Sassari is the highest among all the Sardinian provinces, with a rate 56.8% in men 
and 28.1% in women. Unemployment rate is 10.3% in the male and 20% in the 
female population.  
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1.6. Epidemiology of MS in Sardinia 
Descriptive epidemiology 
MS epidemiology has been investigated in different geographic sub-areas in Sardinia 
over the past 40 years mostly by means of multiple assessments and common 
methodology (Figure 2). Prevalence and incidence rates are summarized in Tables 2 
and 3.  
 
Figure 2. Sardinian surveyed sub-areas for MS epidemiology 
 
 
Sassari 
Macomer 
Barbagia Alghero 
Tempio N-W Sardinia 
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Table 2. MS prevalence rates (per 100,000) in Sardinia for the period 1941-1998 
Area Pop. Prev.  
year 
N.  
cases 
MS  
classification 
Crude rate   
(95%CIs) 
Adj.  
rate 
F:M 
ratio 
North-central102 600,000 1941-61 100 - 16.7 (-) - - 
Sardinia103 1,448,011 1964 239 McAlpine124 
(def and prob) 
16.5 (-) - - 
Sardinia105 1,473,800 1970s 288 Schumacher125 
(def) 
15-34 (-) - 1.3 
Barbagia106 51,611 1975 21 Allison & Millar126 
Schumacher125  
(def and prob) 
40.7 (25-62) 48.5 a 1.1 
Alghero (health distr)113 77,981 1980 46 Rose127  
(def and prob) 
59 (43.2-78.7) - 2.1 
Barbagia108  49,022 1981 32 Allison & Millar126 
Schumacher125  
(def and prob) 
65.3 (44-93) 77.9 b 1.3 
Macomer111 11,083 1981 10 Schumacher125  
(def) 
90.2 (43-166) - 1.5 
Sassari115  124,588 1985 86 Rose127 
(def and prob) 
69 (55.2-85.6) - 2.7 
North-west (sub-area)116 268,926 1991 276 Poser84 102.6 (91.5-115.0) - 2.5 
Nuoro (prov.) 109 273,768 1993 394 Poser84 143.9 (130.4-158.9) 141.4 b 
149.2 c 
2.2 
Nuoro (prov.) 110 273,146 1994 415 Poser84 151.9 (137.6-167.7) 148.8 b 
156.6 c 
2.2 
Sassari (prov.) 123 454,904 1997 686 Poser84 144.4 (134-155.6) d 
150.8 (-) e 
149.7 (139.1-161.1)f 
140.9 g 
153.3 h 
2.5 
Nuoro (prov.)65 272,992 1998 428 Poser84 157 (143-173) - 2.3 
a  1975 Italian population 
b  1981 Italian census population 
c European population 
d 1997 Sassari province population 
e 1991 Sassari province census population 
f  onset-adjusted prevalence rate 
g  1996 Italian population 
h  1991 Italian census population 
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Table 3. Studies of MS incidence carried out in Sardinia during the past three 
decades 
Area Mean 
pop 
Inc. 
interval 
N. 
cases 
MS  
classification 
Crude rate  
(95%CIs) 
Adjust.  
rate 
F:M 
ratio 
Barbagia108 52,885 1961-80 31 Allison and Millar126 
Schumacher125  
(def and prob) 
2.9 (1.9-4.1) 3.2a 1.4 
  1961-70 15  2.7 (1.5-4.4)  1.1 
  1971-80 16  3.1 (1.8-5.0)  1.7 
        
Macomer111 9,028 1912-81 13 Schumacher125 (def) 4.8 (2.5-8.2) - 1.6 
  1957-61   10.2 (-)b  3.0 
        
Alghero (health distr.)113 76,450 1971-80 31 Rose127 (def and 
prob) 
4.1 (2.7-5.7) - 2.1 
  1971-75 10  2.6 (-)  - 
  1976-80 21  5.4 (-) c  - 
        
Sassari115 111,598 1965-85 79 Rose127 3.4 (2.7-4.2) - 2.7 
  1965-75 24  2.1 (1.3-3.1)   
  1976-85 55  4.6 (3.5-6.0) d   
        
North-west116 268,926 1962-91 277 Poser84 5.7 (4.5-7.1) - 2.5 
  1962-66 24  2.0 (1.3-3.0)  2.0 
  1987-91 75  5.7 (4.5-7.1)  3.7 
        
Nuoro (prov.)110 273,248 1955-95 469 Poser84 4.2 (3.8-4.6) 4.3e,f 2.0 
  1955-59 26  2.0 (1.3-2.9)   
  1985-89 91  6.6 (5.3-8.1)   
  1990-95 104  6.4 (5.3-7.8) g   
        
Sassari (prov.)123 431,670 1968-97 637 Poser84 4.9 (4.6-5.3) - 2.5 
  1968-72 39  2.0 (1.4-2.7)  1.6 
  1993-97 158  6.8 (5.8-7.9) h  2.2 
        
a 1971 Italian census population 
b peak incidence 
c Alghero Health District: significant difference between 1971-75 and 1976-80 (chi-square = 3.856, p<0.05) 
d Sassari municipality: significant difference between 1965-75 and 1976-85 (chi-square = 11.25, p<0.001) 
e 1981 Italian census population 
f European population 
g Nuoro province: significant difference during the last 6-year period considered (chi-square = 91.48, p<0.001) 
h Sassari province: significant difference during the study period (chi-square, p=0.02) 
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The first epidemiological study of MS in Sardinia was published over 40 years 
ago.102 This survey was based on 100 cases observed between 1941 and 1961at the 
Inst. of Clinical Neurology, University of Sassari, the referral health structure for 
northern and central Sardinia and covering a population of 600,000 ca. The morbidity 
ratio, i.e., the ratio between observed MS patients and the general population was 
16.7 per 100,000, ranging from 13.3 in the coastal areas to 31.1 in mountainous areas 
(higher than 600 m), though not significant. Based on this study, investigations were 
extended to the entire island where an overall prevalence of 16.5 per 100,000 in 1964 
was estimated103 with significant differences in the rates among the three provinces 
(the province of Oristano had not yet been established): 11.6 in the province of 
Cagliari, 24.8 for Nuoro, and 15.9 for Sassari. These rates were likely to be grossly 
underestimated due to a long time lag between clinical onset and diagnosis at that 
time, expected to be 3- to 4-fold greater than the time interval between the prevalence 
and the study year. Furthermore, case collection was mostly one single source 
hospital-based. Confidence intervals were not reported so no true comparisons 
between rates could be made. 
The first study on incidence in Sardinia refers to year 1971 and showed a rate of 12.5 
per 100,000 per year, with a woman-man ratio of 1.8.104 Mean age at onset was 27.3 
years, lower than that found for other European and northern and central Italian 
populations at that time.  
Of note, this was also the first study conducted by the current main epidemiological 
research group in Sardinia lead by Prof. G. Rosati and Prof. E. Granieri (University 
of Sassari and Ferrara, respectively), which incorporates most of this work co-
authorship. Epidemiological data of Sardinian MS patients with onset since 1955 
have been reviewed by these researchers that have since then shared same survey 
methodology.  
Since early times there has been an interest in investigating spatial variation of MS in 
Sardinia, with special regards to altitude and climate. Higher rates were tendentially 
observed for interior mountain and hill areas as compared to coastal hill plain 
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areas.105 A positive correlation of the distribution of MS with the distribution of 
rheumatic heart disease and post-streptococcal nephritis was described, which 
suggested that MS followed an infection similarly distributed to streptococcal 
infections.  
In 1975 a prevalence of 40.7 per 100,000 and a mean age at onset of 28 years were 
reported in Barbagia, central Sardinia (50,000 pop. ca.).106 This rate was higher than 
any other ever observed in Italy or southern Europe at that time, and was the first 
epidemiological evidence against the theory of a rate drop in the Mediterranean 
area.107 The authors tended to exclude bias due to a change in the population structure 
between 1960 and 1980, and a reduction of at-risk general population due to 
emigration for socio-economic purposes. Subsequent surveys conducted in the same 
area showed that prevalence increased to 65.3 in 1981,108 to 143.9 in 1993,109 to 152 
in 1994110 and to 157 in 1998.65 The latest three updates came from prevalence 
surveys conducted on the whole province of Nuoro, of which Barbagia is a core sub-
area (20% of the province pop. circa). Mean annual incidence rates were stable 
around 3 per 100,000 for the time interval 1961-80,108 but significantly increased up 
to 6.4 in 1990-95 for the whole province.110 The authors could not explain such 
increase simply with improved case ascertainment and prolonged survival over time, 
but suggested that genetic susceptibility might account for absolute higher rates, and 
environmental factors for the temporal increasing trend. 
An incidence study on secular MS trends was conducted in Macomer, central 
Sardinia in 1980s.111 Intensive search for all MS cases occurring in this commune 
since 1912 indicated that MS was absent up to 1952, and that 13 cases had their 
clinical onset in the commune in the years 1952-81. During this period, the average 
annual incidence was 4.8 per 100,000, peaking in 1957-61 with 10.2 and slowly 
decreasing up to 1981. The author suggested an epidemic of MS in this ‘naïve’ 
population starting after 1945, hypothetically secondary to an influx of a high risk 
population from the mainland after the end of World War II. At that time similar 
 
 
33 
evidences were being reported for the Faroe Islands, where MS was hypothesised to 
have started after the British occupation during World War II.112 
The health district of Alghero, north-western Sardinia was later investigated by 
means of population-based design.113 The prevalence in 1980 was 59 per 100,000, 
and the mean annual incidence rate for the period 1971-80 was 4.1 per 100,000, with 
a significant increase from 2.6 in 1971-75 to 5.4 in 1976-80. Mean age at onset was 
25.7 years. The study confirmed the high and increasing risk for MS in Sardinia, with 
special regards to the last 10 year-period during which 72% of the patients had their 
onset. The action of an exogenous (infectious) agent was hypothesised. A prevalence 
rate of 100 per 100,000 was also recorded in the town of Tempio in early 1990s.114   
Same etiological agents were believed to determine MS in a study of the commune of 
Sassari, north-western Sardinia, where prevalence was 69 per 100,000 in 1985, and 
an increase in the mean annual incidence from 2.1 to 4.6 per 100,000 in 1965-75 and 
1976-85, respectively, was observed.115  
Later on, a population-based survey was conducted in the island north-western area 
(270,000 pop. ca) aimed at overcoming biases deriving from small population 
sizes.116 The prevalence rate of 102.6 per 100,000 in 1991 was again the highest ever 
reported for Italy in comparable times. A gradual significant increase in mean annual 
incidence rates in the study time 1962-91 was observed up to 5.7 per 100,000 in the 
last quinquennium considered. The attempt to find sub-areas at higher disease 
occurrence failed to produce any evidence. In this paper, the possibility for case 
ascertainment bias due to improved diagnostic facilities and higher awareness of the 
disease was discussed. However, the comparison of Sardinian rates with those from 
areas with higher diagnostic standards and easier access to facilities pointed, at least 
partially, to a true rising risk of MS in Sardinians. In the meantime, immunogenetic 
studies conducted in Sardinia indicated a positive association with HLA-D4 and 
DQB1*0201 and *0302 alleles possibly conferring a genetically based susceptibility 
to MS and other immune mediated disorders such as juvenile diabetes (IDDM),117-121 
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which featured, among Sardinians, an epidemiological behaviour surprisingly similar 
to MS.122  
The largest population-based survey was conducted in Sardinia in the province of 
Sassari (455,000 pop. ca.).123 A prevalence of 144.4 in 1997 and an incidence of 6.8 
in 1993-97 with a significant increase from 2.0 in 1968-72 were reported, close to 
parallel to what registered for the province of Nuoro with independent assessment but 
same methodology in comparable time. 
Across these descriptive epidemiological surveys, different diagnostic criteria for MS 
were used from time to time, and namely the McAlpine’s criteria124 for definite and 
probable MS in Caruso et al,103 the Schumacher Committee criteria125 for clinically 
definite MS in Rosati et al,105 the Schumacher Committee criteria125 for definite and 
probable MS and Allison and Millar criteria126in Granieri and Rosati,106 Granieri et 
al,108 the Rose criteria127 for definite and probable MS in Rosati et al,113,115 and the 
Poser et al criteria84 in Rosati et al,116 Casetta et al,117 Granieri et al,110 and Pugliatti et 
al.123 
For prevalence studies Poser et al criteria were used since prevalence year 1991. For 
incidence studies an overlap of different criteria for same time intervals occurred 
from different studies. In Rosati et al (1996) Poser criteria were used for the 
incidence interval 1962-91, this means that patients that had been included in 
previous studies and diagnosed prior to 1983 were reclassified from Rose criteria. 
The geographical variation of MS prevalence in the province of Nuoro was 
investigated by means of Bayesian approach (see Section 1.4.1.) by Montomoli et 
al.65 The Bayesian prevalence rates ranged from 143 to 262 per 100,000, with 
clustering being significant for four communes (Nuoro, Oliena, Fonni and Desulo). 
Based on the high number of multiplex families and the peculiar genetic asset of this 
population, the authors interpreted their findings as correlated to a higher 
susceptibility on a genetic basis. 
Genetic epidemiology 
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The genetic hypothesis has been the focus of a study on the disease recurrence risk in 
siblings of MS patients in the same population.128 A risk of 4.7% and a risk ratio of 
31 to the general population were reported. MS recurrence risk was positively 
influenced by age at onset, partly by probands’ female gender, and by an interaction 
between both factors. Based on the number and distribution of affected relatives in 
the family, the authors proposed a hereditary model for the disease transmission 
consisting of a single dominant gene with an extremely low penetrance. The same 
analysis of was then extended in the same population with regards to first-, second-, 
and third-degree relatives.129 The study, conducted on 313 MS probands and 12,717 
relatives, showed an overall age-adjusted recurrence risk in relatives of 1.90% 
(95%CIs, 1.57-2.30), 1.26% (95%CIs, 0.60-2.63) in parents, 2.33% (95%CIs, 0.09-
5.56) in children, 4.76% (95%CI s, 3.57-6.32) in siblings, 0.72% (95%CIs, 0.42-
1.22) in second-degree relatives, and 1.79% (95%CIs, 1.27-2.51) in third-degree 
relatives. The gender of the probands (male) and of the relatives (female), and the 
number of affected relatives in the family significantly increased the familial 
recurrence risk for MS. These observations are in line with what we observed in the 
population of the province of Sassari, based on 418 probands and 18,799 relatives 
(Pugliatti et al, unpublished data). 
Familial aggregation and the contribution of genetic factors to familial clustering of 
MS patients were studied in a southern region of the island,130 which lacks, however, 
systematic descriptive epidemiological data. Recurrence risk in siblings for 901 
Sardinian patients and factors influencing risk (patients’ and siblings’ gender, 
patients’ age at onset, siblings’ birth cohort, and presence of affected relatives other 
than siblings) were examined. Further, the presence of distant familial relationships 
among patients was evaluated by tracing the extended pedigrees of all patients with 
MS born in one Sardinian village. Recurrence risk was 2.3-fold increased in siblings 
of index patients with onset age less than 30 years and 2.9-fold when having a 
relative with MS other than a sibling or parent. Pedigree analysis of patients from the 
village showed that all 11 patients descended from 3 pairs of ancestors, whereas no 
cases occurred in the remaining village population. The authors argued in favour of 
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MS familial aggregation in Sardinians being influenced by genetic factors and, by 
means of independent observations, that isolation and founder effect caused 
enrichment of "etiologic" MS genes. 
The distinct HLA association of MS in Sardinia supports this interpretation. A 
number of molecular genetic studies have been conducted by different research 
groups, aimed at disclosing associations between HLA haplotypes or individual 
susceptibility genes with MS in this population.22 Initially, association and linkage 
studies performed  in independent datasets using the transmission disequilibrium test 
(TDT),131 demonstrated Sardinian MS in linkage disequilibrium with two different 
DRB1 alleles: DRB1*0301 (DR3) and DRB1*0405 (DR4).118,132 On the contrary, the 
DRB1*1601, a DR2 allele different from the DRB1*1501-DR2 which confers MS 
susceptibility in Caucasian, was associated with a low risk of developing MS.120 The 
analysis of allelic variation at candidate loci confirmed MS association with both the 
Sardinian-specific DRB1*0405-DQA1*0501-DQB1*0301 and DRB1*0301-
DQA1*0501-DQB1*0201 haplotypes.133 However, a comparative analysis of the 
DRB1, DQA1 and DQB1 could not identify individual loci explaining MS 
predisposition. Other HLA gene(s), in linkage disequilibrium with the ‘Sardinian’ 
HLA-DRB1-DQA1-DQB1 haplotype, such as IFNγ gene polymorphisms, might be 
primarily or co-responsible for genetic susceptibility to the disease.134 Subsequent 
immunogenetic studies indicated that at least part of the HLA-based MS 
susceptibility in DR3+ Sardinian MS patients was supported by an impaired IL-10 
production from mononuclear cells.135 MS predisposition in DR4+ MS patients might 
depend on an abnormally high level of TNFα production.135,136  
More recently, full genome searches on large numbers of affected sibling pairs have 
been conducted at multiregional level, including Sardinia.137 Initial results only 
addressed to regions of common interest in MS susceptibility located on chromosome 
6, within the HLA region, chromosomes 3, 18 and 17, but later meta-analyses 
disproved such results.  
Environmental epidemiology 
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Recent studies have been conducted by our research group aimed at investigating the 
role on MS-associated retrovirus (MSRV) in Sardinian patients as compared to 
Sardinian healthy controls.138,139 MSRV is an exogenous member of the HERV-W 
family that has been found in plasma and CSF of many patients with MS.140 The 
extracellular form of MSRV was detectable in 100% of plasma samples from active, 
untreated MS patients and in 12% of healthy controls from Sardinia. Over an 
observational period of 3 years, patients with MSRV-free CSF had a stable MS 
course, whereas those with MSRV+ CSF disclosed a more severe, treatment-
requiring disease, suggesting the prognostic value of MSRV in the CSF at onset.134,141 
However, since titers of MSRV were found to be higher in other inflammatory as 
compared to other non inflammatory central nervous system diseases, a strict 
etiologic role in MS can be ruled out.138  
1.7. Perceived health status and mild MS.  
In the past 30 years, the interest in the concept of quality of life has increased 
significantly, both in research and clinical practice. Based on their application and the 
main objectives, the studies on MS quality of life may be classified into three 
categories:142 (i) evaluating the development and validity of quality of life 
questionnaires and clinical scales, (ii) evaluating determinants of quality of life or 
comparing the quality of life among various groups, and (iii) using quality of life as 
outcome measures in clinical trials and other interventions.142-144 Quality of life as 
outcome measure is especially indicated for patients with chronic disorders for whom 
other more clinical and biological parameters could be less informative to judge 
interventions efficacy. 
The increasing interest in quality of life in health care is explained by (i) the 
increased life expectancy resulting from improved medical therapies with an impact 
on health outcomes such as morbidity and mortality, and (ii) the proliferation and 
advancement of medical and surgical technologies and subsequent necessary 
consideration of the benefit-burden or -cost ratio of equivalent therapies.144 Today, 
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research on quality of life can affect how policy makers allocate health care resources 
or determine reimbursement policies.  
Despite the increasing interest in this topic, consensus is lacking on the definition of 
quality of life and on whether it is measurable or not, making it an ambiguous 
concept. Quality of life is used as an umbrella term,145 covering a variety of concepts, 
such as functioning, health status, perceptions, life conditions, behaviour, happiness, 
lifestyle, symptoms, etc. Several concept analyses today suggest that quality of life 
ought to be defined in terms of life satisfaction.144,146-148 A wide spectrum of quality 
of life definitions exists in the literature, which can be grouped into the following 
broad categories: (1) normal life, (2) utility, (3) social utility, (4) happiness/affect, (5) 
satisfaction with life, (6) satisfaction with specific domains, (7) achievement of 
personal goals, and (8) natural capacities.144 
‘Quality of life’, ‘health status’ and ‘functional status’ are often used interchangeably 
under the assumption that a fully health life is identical to a high quality life.144 It is 
not so, and quality of life and health status are two different concepts, as shown with 
the “disability paradox”: physically disabled persons unexpectedly experience a good 
quality of life, although most observers assume that these people have an undesirable 
life.149 The interchangeable use of quality of life, health and functional status is 
reflected in the measurement of these concepts, such as the 36-Item Short Form 
Health Survey (SF-36),150 which is erroneously used to measure quality of life, or 
‘health-related quality of life’, because it truly measures individuals’ perceived health 
status.151 Furthermore, while measuring health status reflects objective dimensions, 
physical functioning and observable life conditions, quality of life should be a purely 
subjective experience, determined by one’s subjective appraisal of one’s life 
conditions. Objectively measured indicators of living conditions were found to 
account for 15% of an individuals’ quality of life,152 which therefore has more to do 
with subjective well-being and life satisfaction. 
Another important distinction in quality of life studies is between indicators and 
determinants.144 Indicators are events or conditions that typically characterise a 
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specific situation, whereas determinants are the elements that determine the nature of 
the situation itself. Some factors, such as employment status, can be both indicators 
and determinants in quality of life research, depending on a priori assumptions. In 
this respect, ‘health status’ should be considered one of the determinants of quality of 
life in that it contributes or influences it, and not an indicator.  
Quality of life is not a static concept. It changes due to age-related perspectives, life 
events, changes in values and priorities, and coping abilities. Personality and “sense 
of coherence” also influence it.153 Nevertheless, it is unlikely to be a very highly 
dynamic concept and its daily fluctuations are probably not relevant within one 
period of time. 
Health is always considered a very important aspect of quality of life. ‘Health-related 
quality of life’ has been developed to describe aspects of individual’s subjective 
experience related to his/her health status, disease and disability, within the World 
Health Organization (WHO) definition of health, as ‘a state of complete physical, 
mental and social well-being and not merely the absence of disease or infirmity’.154 
Focusing on health-related quality of life, researchers end up with overestimating the 
impact of the health status in quality of life and underestimating other aspects of life. 
As already stated, measuring health-related quality of life is often actually measuring 
patients’ perceived health status.151 
MS patients score lower in health-related quality of life than do patients with other 
chronic and disabling conditions such as epilepsy, diabetes, rheumatoid arthritis or 
inflammatory bowel disease.155-156 Nortvedt et al143 conducted a study aimed at 
describing the perceived burden of MS using a structured quality of life instrument in 
a Norwegian MS population-based sample and comparing these scores with those in 
a general population. The patients showed markedly and significantly lower mean 
scores for all perceived health dimensions measured with SF-36 compared with age- 
and gender-matched general population. This difference was especially high for 
physical functioning, general health, role limitation of physical functioning, vitality, 
and social functioning. They also showed that the EDSS score correlated significantly 
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and negatively with all SF-36 health dimensions except bodily pain, the highest 
coefficients being observed for physical functioning, social functioning, and general 
health. The EDSS could explain 73% of the variation in physical functioning, 23% in 
social functioning, and 21% in general health, and little for the other dimensions. 
In clinical practice, the strategies aimed at improving MS patients’ health-related 
quality of life most frequently focus on patients with greater disability. Health 
professionals perceive more severe physical impairment as a determinant of patients’ 
poorer quality of life,157 whereas physical functioning among non or mildly disabled 
MS patients is not usually matter for concern.  
The rating scales commonly used to measure physical impairment, such as the 
Expanded Disability Status Scale (EDSS),158 almost exclusively reflect health 
professionals’ objective assessment. The patients’ self-perception of their health 
status - what ultimately counts in quality of life - can be overlooked, particularly 
among those with no or little physical impairment.  
The studies aimed at investigating health-related quality of life and self-perceived 
health status among MS patients have mostly been conducted on patients with a wide 
range of disability (i.e., including severely physically impaired patients).142 Despite a 
growing interest in MS early stage, i.e., in the benign disease and clinically isolated 
syndromes (CIS), little focus has so far been given on health-related quality of life 
and self-perceived health status in non or mildly disabled MS patients, as defined 
from objective measurement. 
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2. AIMS OF THE STUDY 
The present work builds up based on two broad questions stemming from the 
background epidemiological research on MS discussed above.  
The first issue regards the relevance to use epidemiological descriptive data to 
disclose (i) clues to disease etiology and (ii) to interactions between causative agents 
and the host by attempting at tracing the individuals’ age at which these mechanisms 
(disease induction) occur. 
The second area of interest is the characterisation of health-related quality of life for 
the MS population at large, thus including no or low disabled patients, in order to 
provide more realistic data for implementing cost-of-illness studies and ad hoc health 
policies. 
These two questions have constituted the frame for this work specific objectives, 
which have been individually dealt with in the articles: 
I. To disclose -and characterise -significant prevalence variation at a 
microgeographic level, possible expression of spatial variation in the 
distribution of disease risk factor(s); 
II. To update incidence trends of MS in northern Sardinia, and disclose different 
patterns by time periods, gender, initial clinical course, age of onset and sub-
areas of residence, as a possible expression of temporal variation in the 
distribution of disease risk factor(s); 
III. To assess whether individuals, that later developed MS, during the disease pre-
onset history had been significantly closer to each other in time and space than 
expected by chance, and shared putative common exposure(s) while residing 
in the province of Sassari; if so, at what age was such exposure most likely to 
have occurred; 
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IV.  To investigate the self-perceived health status, with special regards to physical 
functioning, in Sardinian MS patients with no or mild disability at objective 
neurological examination, and as compared to the general population. 
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3. MATERIALS AND METHODS 
An overview of the materials and methods follows. Further details are found in each 
article. 
3.1. Epidemiological data (Paper I-III) 
3.1.1 Study area  
All the four studies were conducted on the population of the province of Sassari, 
northern Sardinia, insular Italy. A summary of main geo-climatic and demographic 
features is reported in Table 4.  
Table 4. The province of Sassari, northern Sardinia: summary of main geo-
climatic, demographic and ethnic main features. 
Area 7,520 kmsq 
Latitude Between 40°30’and 41° N 
Geo-climatic areas: mean annual 
temperature (min-max) 
Coastal area: 16.5° (13.7°-20.5°) 
Interior plain area: 15.9° (9.5°-23.7°) 
Interior hill area: 15.8° (12°-19.1°) 
Interior mountainous area: 12° (7.5°-16.7°). 
N. communes 90 
Population 453,628 in 2001 national census  
381,191 in 1971 national census  
Migration inflow 1.8% in 1997 
Migration outflow 1.6% in 1997 
Geographical sub-areas100 Sassarese, Gallurese, Northern Logudorese, 
Eastern Logudorese, Southern Logudorese, 
Goceano and Algherese (Catalan)  
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Migration flow in this area is modest: in 1997, only 1.8% of the total population 
registered as resident from other Italian provinces and from foreign countries, 
whereas 1.6% moved away from the study area.159 Immigration to the study area is 
mostly from other Sardinian provinces, so the study population almost completely 
consists of native individuals and a stable ethnic composition. The low migration 
flow over time has led to the differentiation and isolation of seven geographic areas 
with internal homogeneous ethnic composition (peculiar historical, linguistic and 
cultural patterns).160,161 A slightly different classification100 of such sub-areas was 
used in Paper II and Paper III as compared to Paper I. 162 In order to avoid 
ambiguity, we shall hereafter refer to the classification by Contini100 as follows: 
Sassarese (1), Gallurese (2), Northern Logudorese (3), Eastern Logudorese (4), 
Southern Logudorese (5), Goceano (6) and Algherese or Catalan (22) sub-areas 
(Figure 3). The same sub-areas indicated by numbers correspond to the following 
denomination as from Paper I: Sassarese (1), Gallurese (2), Northern Logudorese 
(3), the eastern area of Common Logudorese and southern Gallurese (4), Common 
Logudorese (5), Eastern Logudorese (6), and Algherese-Catalan (22). 
All these domains share the same historico-cultural Sardinian heritage, with the 
exception of the Algherese and the Gallurese sub-areas, due to Catalan, and mainland 
Italian and Corsican influence, respectively. 
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Figure 3. Historical, linguistic and ethnic domains in the province of Sassari, 
northern Sardinia 
 
Sub-
area 
Paper I162 Papers II and III100 
   
1 Sassarese Sassarese 
2 Gallurese Gallurese 
3 Northern Logudorese Northern Logudorese 
4 Common Logudorese/Gallurese Eastern Logudorese 
5 Common Logudorese Southern Logudorese 
6 Eastern Logudorese Goceano 
22 Algherese (Catalan) Algherese (Catalan) 
   
NB: the Contini classification100 has been considered throughout the text 
 
Nuoro 
Cagliari 
Oristano 
SASSARI 1 
22 3 
2 
4 
5 6 
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Endogamy has played a role in most inner communities,163 and at a microgeographic 
level, the social structure varies from close communities at high inbreeding rate 
(southern province), to more open communities. A more archaic social structure in 
the innermost regions of Sardinia has also been demonstrated with population-based 
studies conducted on the frequency of mtDNA haplotypes.164  
Consanguinity has involved Sardinians rather heterogeneously over time and space 
and can be a determinant of clustering of both environmental and genetic factors at a 
microgeographic level. Geomorphologic, historical and cultural factors have also 
influenced the frequency and distribution of close communities. Community isolation 
has been reported to be directly proportional to the altitude above sea level and the 
distance from the coastline.163 In northern Sardinia it is higher than in the south, and 
has especially involved the innermost sub-areas of the province of Sassari  
For Paper I, the 1997 population of the province of Sassari, consisting of 460,135 
individuals (227,215 men and 232,920 women) was computed as an interpolation 
from the 1991 census data for the province165 and was used as denominator for 
prevalence rates. Age- and gender-specific populations for each commune were used 
as denominators for specific rates. Based on the 1991 census, the study area 
comprised 89 communes. Each commune was coded according to the Italian Central 
Institute of Statistics Coding.166 
For Papers II and III, the province 2001 census population was used as denominator 
which consisted of 453,628 (222,191 men and 231,437 women).167 Based on the 
2001 census, the study area comprised 90 communes.  
3.1.2. Case ascertainment and data collection 
The University of Sassari is the first university institution in Sardinia started in the 
16th century. The level of medical organization within the study area public health 
care system is relatively high, and the University Hospitals of Sassari have long 
represented the referral health care structure for central and northern Sardinia. The 
level of health care has improved during the study period parallel to a general 
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improvement achieved at national level, as far as quality of diagnostics and access to 
medical facilities and neurological services are concerned. CSF analyses and MRI 
became available for routinely diagnostics for patients admitted to hospital at the 
beginning of 1990s. The Regional Centre for the Diagnosis and Treatment of MS 
(Centro Regionale per la Diagnosi e Cura della Sclerosi Multipla) – hereafter 
referred to as “Sassari MS Centre” - was established by the Sardinian regional 
government at the University Dept. of Clinical Neurology in 1989. In 1996 the 
Sassari MS Centre was commissioned to authorise the prescription of 
immunomodulatory treatments (interferons-beta and glatiramer acetate) for all other 
regional MS Centres or neurological health care providers. 
Given its expertise and diagnostic facilities, virtually all cases of suspected MS refer 
to the Sassari MS Centre from northern and central Sardinia (800,000 pop. ca. 
coverage), and undergo standardised diagnostic procedures including CSF analysis, 
evoked potentials, and MRI. 
For research and patients general management purposes, a Register of MS cases was 
started at the Dept. of Clinical Neurology since 1995. Its characteristics are reported 
in Table 5.  
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Table 5. Sassari province MS case Register: summary of main demographic and 
clinical features* 
Beginning of systematic 
case collection:  
1970s for province sub-areas 
1995 for the whole province 
Survey methodology  Population-based 
“The spider method” 168 
Location Sassari MS Centre, Dept. Clinical Neurology, University of 
Sassari, Sardinia, Italy 
Epidemiological sources - Depts. of Clinical Neurology, University of Sassari 
(medical records, evoked potentials, CSF and 
immunomodulatory drugs lists)  
- Other University Hospitals of Sassari (Ophthalmology, 
Child Neurology, Radiology) 
- Other Neurological Depts. (Hospitals of Ozieri, Olbia, 
province of Nuoro) 
- Cagliari MS Centre 
- National MS Society  
- Centres for Motor Rehabilitation  
- Neurologists in private practice 
- General practitioners in the province of Sassari 
- Extraregional MS Centres (Gallarate General Hospital, 
Don Gnocchi Foundation in Milan) 
- Official death certificates 
Total n. cases included  1221 (352 men and 869 women)  
Distribution Province of Sassari                  1073 (87.9%) 
Other Sardinian provinces           70 (5.7%) 
Other                                            78 (6.4%) 
N. deceased 76 (34 men, 42 women) (1938-2004) 
Mean age at death (SD) Men: 53.4 (13.1) years  
Women: 52.1 (13.5) years  
Mean current age (SD) 
(N=1209) 
Men: 49.5 (15.7) years  
Women: 47.9 (13.9) years  
MS classification84 (N=745) CDMS  639 (85.8%) 
LSDMS  21 (2.8%) 
CPMS    77 (10.3%) 
LSPMS    8 (1.1%) 
Information collected Population-based: 
- demographic (gender, place/date of birth, changes of 
residence since birth) 
- clinical (date of onset and diagnosis, onset symptoms, 
disease classification, disease course, degree of 
disability, immunoprophylactic treatments, comorbidity) 
Sub-studies: 
- familial occurrence of MS and other immune mediated 
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disorders 
- environmental exposure history 
- education 
- socio-demographic 
- health-related quality of life 
* as to August 2006 
 
The type of survey methodology used to find MS cases has been described as the 
spider method.168 In this model, MS patients are not sought by investigators, but 
rather they are caught in a network of local health operators displayed and normally 
practising throughout the study area who refer them or notify them to one main 
central health care provider where registry occurs periodically. Our Dept. of Clinical 
Neurology and the MS case Register represent such referral structure receiving 
notifications by other peripheral sources in the territory (Table 5). The repeated case 
ascertainments carried out in the province of Sassari prior to the present 
work113,115,116,123 have largely contributed better accuracy to the Register. 
Patients were included in the Register with a diagnosis of MS according to the Poser 
et al. criteria84 for clinical or laboratory supported definite (CDMS, LSDMS) and 
probable (CPMS, LSPMS) MS. For Paper I, 87.6%, 2.7%, 8.4%, and 1.2% of the 
patients were classified as having CDMS, LSDMS, CPMS and LSPMS, respectively. 
In addition to fulfilling the Poser criteria, after 1986 diagnostic MRI was performed 
in 92% of patients. Prior to that date, diagnosis was almost exclusively based on 
clinical and paraclinical evidence, and for 78% of cases on the CSF immunological 
study. Other autoimmune, immunomediated and infectious diseases such as primary 
and secondary central nervous system vasculitides, post-infectious 
leukoencephalopathies and other demyelinating disorders were ruled out with support 
of laboratory tests and neuroimaging.  
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3.1.3. Study designs  
In Paper I, to disclose geographical variation of the disease in the province of 
Sassari, a hierarchical Bayesian approach was applied to a spatial cluster analysis of 
the distribution of 1997 prevalence rates in each commune. The theory behind this 
type of analysis has been reported in detail in Section 1.4.1. A prevalent case was 
defined any individual who resided in the province of Sassari on prevalence day Dec. 
31st 1997. Although spatial cluster analysis is not primarily intended for investigating 
on the disease latent period, an attempt at disclosing spatial clusters of disease at 
individuals’ age of 5-15 years was performed, by mapping the distribution of all 
registered cases by commune of residence at that age.  
The study designs adopted for Paper II and III were incidence-based. Incidence 
interval spanned from 1965 and 1999. An incident case was defined as any individual 
who first experienced symptoms later related to MS32 while residing in the province 
of Sassari within the incidence interval considered. With special regards to Paper II, 
incidence rates by time periods, gender, initial clinical course, age of onset and 
province sub-areas of residence (Figure 3) were analysed. The initial clinical course 
was retrospectively categorised into relapsing remitting (RR) course or progressive 
course. 
In Paper III, to investigate whether individuals that later developed MS had shared 
exposures to putative causative agents concentrated in the same area and over the 
same time span, and at which age such exposure might have occurred, a space-time 
cluster analysis of MS in the province of Sassari, was conducted based on incident 
cases. The theory behind this method was described in details in Section 1.4.3. 
Changes in residences by commune from birth to MS onset were collected from the 
Register. Patients within the same birth cohort were tested for having lived 
significantly closer to each other than expected169 and in relation to clinical features, 
such as disease course and age at onset.170 Time closeness interval for each pair was 
arbitrarily chosen at 1, 2 and 5 years. The statistical model applied for communes was 
also applied to sub-areas (Figure 3). 
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In order to disclose whether space-time clustering depended on demographic and 
clinical features, the analysis was run in groups of patients stratified by gender, age at 
onset (less than versus 30 years or above), initial course of the disease (RR or 
progressive), cohorts by birth and clinical onset and sub-areas. 
3.1.4. Statistical analysis  
For Paper I, the first step was calculating the area age- and gender-specific 
prevalence rates (expressed as the number of cases per 100,000 population) using the 
1997 population and mapping them for each commune of the province of Sassari. In 
order to remove possible biases due to different age– and gender-structures for 
different areas, standardised rates were calculated by the direct method of adjustment 
using the same standard population and assuming an equal number in each age 
group.171 Since the area-specific number of cases is small, traditional statistical 
methods tend to yield very extreme rates due to the strong influence of random 
variation. To overcome this problem, a hierarchical Bayesian approach was adopted 
which eliminates extreme values from the map and yields smoothed estimates of 
disease rates (see Section 1.4.1). This method best reflects the true geographical risk 
variation which is epidemiologically more interpretable. Since the data set consists of 
prevalence rates, the binomial model was assumed to obtain the Bayesian estimates 
via Gibbs sampling172-175 on BUGS software.176 In order to explain the amount of 
variation of the true prevalence rates in the map, a combination of degree of freedom 
and scale factor was chosen for the prior distribution of the hyperparameter.66,70 A 
sensitivity analysis allowed us to choose the values of ten as degrees of freedom and 
two as scale factor for this work. The reference value used to produce the PP of a 
prevalence rate was the median value of generated samples.  
The model was fitted in order to map the area specific prevalence rates for patients 
residing in the study area both on prevalence day and during the age 5 to 15. Because 
of the conspicuous number of areas containing zero cases among men, the gender-
specific Bayesian approach was applied only to women. Three separated chains 
starting from different initial values were run for each model: total (i.e., both 
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genders), women, and total 5-15. The Bayesian prevalence estimates and tests were 
obtained after convergence of the hyperparameter via the Gibbs sampler, discarding 
the first 1,000 iterations of each run as burn-in or pre-convergence samples. 
Convergence at 10,000 iterations was checked by visual examination of sample traces 
by Geweke’s diagnostic177 implemented in the CODA software.178 
For Paper II incidence rates were calculated using data from the census in 1971, 
1981, 1991 and 2001. Age standardization was computed by adjusting for the general 
population of Italy as of the 2001 census.179 The time period of onset 1965–99 was 
divided into seven 5-year intervals. A chi-square test was applied to test any 
difference in incidence over these 5-year intervals between gender, initial clinical 
course, symptoms and areas of onset.  
For Paper III, the Knox’s method was used,180 in which all pairs of patients are 
defined as close or not close in time according to a cut-off point in number of years, 
and close or not close in space according to some geographical cut-off point. The 
interval for defining temporal closeness for each pair of patients was arbitrarily 
chosen at 1, 2 and 5 years: for 1-year closeness, patients were considered to be 
temporally close if they were born the same year, the year before or the year after. 
Spatial closeness was defined as residing in the same commune. 
The observed number of pairs of patients close in both time and space was compared 
with the expected number calculated according to a normal two-by-two table (Table 
6), where A represents the number of pairs close in both time and space, B represents 
pairs close in space but not in time and C pairs close in time but not in space.54 The 
ratio between observed and expected close pairs was calculated, and values above 
unity indicated an excess of clustering.  
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Table 6. Two-by-two table for space-time cluster analysis180 
  Distance between pairs 
of patients in space 
 
 Close Not close  
Close A C A+C 
Distance 
between pairs 
of patients in 
time   Not close B D B+D 
  A+B C+D A+B+C+D 
 
Expected (E) number of pairs close in time and space: E = (A+B)*(A+C)/ [n(n-1)]/2  
Observed number of pairs close in time and space = A. Observed-to-expected ratio = 
E/A 
 
The statistical significance of deviation from unity for this ratio is often calculated 
based on an assumption of a Poisson distribution of the observed number of pairs 
close, A. However, since there is structural dependency in this table caused by each 
patient participating in (n-1) pairs, the assumption of a Poisson distribution does not 
hold. Because many test statistics do not have a standard asymptotic distribution, or if 
they do, it may not be reliable in realistic sample sizes and may be too 
computationally exhaustive to calculate the exact sampling distribution through 
exhaustive enumeration of all possible samples, the Monte Carlo empirical p-values 
are calculated. These approximate the exact p-value without relying on asymptotic 
distributional theory or exhaustive enumeration. Simulation studies have shown that 
using the Poisson distribution produces too optimistic p-values (Riise, personal 
communication). Therefore, empirical p-values were in this study calculated using 
100,000 Monte Carlo simulations by randomly assigning the municipalities of 
 
 
54 
residence to the patients.181 The empirical distribution of the ratio between observed 
and expected close pairs was then used to estimate the p value for the actual ratio. 
The analysis included 649 MS patients with information on changes of commune of 
residence until at least age 15 years. This yielded 210,276 pairs [n(n – 1)/2 = 
649*648/2] for statistical analysis. 
In order to find the age of highest clustering the analyses were repeated using the 
residing commune each year from year of birth until age 25 years (or onset if before 
this age). Secondly, to reveal a fixed latency induction period, closeness in time and 
space was analysed for each year from the year of clinical onset backwards to the 
year of birth. In this case, a cluster meant an excessive number of pairs of patients 
had lived in the same commune during a time period corresponding to a fixed number 
of years prior to the onset for these patients. Cases living outside the province of 
Sassari at the specific age under study were excluded at this age. 
At the age of most clustering, 1 year, we also performed space-time cluster analysis 
in subgroups according to gender and clinical characteristics: age of clinical onset 
(30 versus >30 years), type of initial clinical course (RR versus progressive), birth 
year (1959 and >1959, where 1959 was the median of the total distribution of years 
of birth) and geographic sub-areas. Two large sub-areas were defined according to 
similar environmental and ethnic features: a western sub-area including areas 1, 3 and 
22 and an eastern sub-area including areas 2, 4, 5 and 6. The statistical significance 
for subanalyses was calculated using Monte Carlo simulations as described above. 
To examine whether the clustering was related to age at onset, we compared the mean 
age at onset in the group of clustered cases (patients participating in at least one close 
pair) and the group of non-cluster cases (patients not participating in any close pair). 
The difference was tested using a t-test. 
For Paper II and Paper III, the SPSS for Windows version 13.0 statistical software 
(SPSS Inc., Chicago, IL, USA) was used for all analyses.  
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3.2. Self-perceived health status in MS (Paper IV) 
3.2.1. Study population 
For Paper IV, the patients were recruited through the MS Register among those that 
had consecutively referred to the Centre for clinical follow-up from Jan.1st to Dec. 
31st, 2004. Inclusion criteria comprised fully ambulatory status (EDSS score 3.5 or 
less)158 and MS clinical onset32 between 1965 and 2004. Exclusion criteria were 
comorbidity (chronic disorders) and an exacerbating phase of the disease within the 
previous 3 months. Clinical information, including EDSS scores and disease course 
was purposely updated during a neurological examination performed at the time of 
the study. The disease course was categorized into three classes: RR, relapsing-
progressive/secondary progressive and primary progressive.182 
3.2.2. Measures  
The EDSS was used to assess disability. In 1955 Kurtzke described the Disability 
Status Scale (DSS), a new scale for evaluating disability in MS especially devised as 
an outcome measure in clinical trials.183 The DSS had 10 grades from 0 (normal) to 
status 10 (death due to MS). The scale was intended to measure the maximal function 
of each patient as limited by neurologic deficits. It was based only on objectively 
verifiable deficits due to MS assessed with neurologic examination were included, so 
symptoms were discarded. The final DSS score was based on the scores by 
Functional Systems (FS) which included the pyramidal, cerebellar, brainstem, 
sensory, bowel and bladder, visual, cerebral or mental, and other or miscellaneous 
functions. The FS were mutually exclusive in terms of neuroanatomy, but together 
comprised all neurologic abnormalities on examination that could be attributed to MS 
lesions. The FS were not additive, i.e., each FS could be compared only with itself 
over time. For this reason DSS scores had to be used for overall comparison of the 
same patient at different examinations. 
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In 1983 the Expanded DSS (EDSS) (Annex I) replaced the DSS, based on the 
believed poor sensitivity of the DSS to changes in the middle ranges. The relative 
weight of FS in EDSS became even greater than for DSS.  
The patients’ self-perceived mental and physical health status was measured using the 
SF-36 (Annex II).150,184 SF-36 is a generic health survey measure assessing the most 
relevant health domains to both diseased and healthy individuals. SF-36 was 
purposely chosen as it allows comparisons between MS patients and a reference 
population by virtue of its construct, psychometric properties and external validity 
(robustness and generalisability).184,185 The SF-36 is among the most widely used 
rating scales for measuring self-perceived health status among MS patients.142 The 
SF-36 explores eight main domains: physical functioning, role limitations due to 
physical health problems (role–physical), bodily pain, general health, vitality, social 
functioning, role limitations due to emotional health problems (role–emotional) and 
mental health. The first four subscales primarily measure physical health and the last 
four primarily measure mental health. The general health and vitality subscales are 
sensitive to both physical and mental health. 
Normative SF-36 data by gender and age are available for the general population of 
Italy.186,187 The normative sample was studied in 1995 and consisted of 2031 
individuals, 1032 (50.8%) women and 999 (49.2%) men with a mean age of 47.7 
years. The sample is representative of the general population, with 37% of 
respondents residing in southern Italy. Detailed sampling procedures and further 
sample features are reported in Paper IV, and in Apolone and Mosconi.187 
3.2.3. Procedures 
The SF-36 Italian standard version187 was administered to the patients at the hospital 
setting. The questionnaire content was outlined to the patients in a standardised way. 
Cognitive impairment can also be detected in mildly disabled MS patients.188,189 To 
overcome potential interference with reliable responses to questionnaires, the Raven 
Coloured Progressive Matrices (RCPM) test190 was used to screen for major 
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intellectual deficits. RCPM is a nonverbal intelligence test based on perceptual ability 
and visuospatial reasoning. RCPM raw scores were age-adjusted according to 
normative data (Raven et al, 1998).190 MS patients with an RCPM score 
corresponding to an intelligence quotient (IQ) of 69 or higher190 were included in the 
study. 
3.2.4. Statistical analysis 
The SF-36 scores and substitutions for missing values were calculated according to 
standardised procedures described elsewhere.184 Scores were transformed to a 0 
(minimum) to 100 (maximum) scales. The statistical analysis was performed only for 
the domains with 50% or more complete items and after substituting missing values. 
The single subscale scores and not the composite ones were analysed due to their 
better psychometric properties. The analysis was based on 35 items, as the 
transitional health status item was not included. 
SF-36 subscale scores were then standardised to the general population of Italy, and z 
scores were calculated for each subscale using the mean (SD) of the age and gender-
specific reference norms. These scores were then rescaled to a mean (SD) of 50 (10), 
which was therefore the average score for the general population of Italy on any 
subscale. These standardised scores were then compared between the MS patients and 
general population. One-sample t-tests were used in comparing the standardised 
subscale scores for the MS population with the data from the general population. 
The association between EDSS and the physical functioning subscale was estimated 
using Pearson correlation coefficients. The impact of physical functioning on self-
perceived health status was assessed by estimating the regression coefficients using 
physical functioning as an independent variable and each of the other subscales as a 
dependent variable in separate regression analyses. The regression coefficients 
between the physical functioning subscale and the other SF-36 subscales were 
estimated for the MS patients and the general population and also by gender. 
Significant differences in these regression coefficients between the subgroups were 
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tested using univariate analysis of covariance (ANCOVA) with each SF-36 subscale 
score as dependent variable, group (MS patients and the general population) and 
gender as a fixed factors and the physical functioning subscale as covariate. A 
significant interaction effect between the physical functioning subscale and group 
status in this model was interpreted as a significant difference in the corresponding 
regression coefficients. 
Significance was set at p < 0.05, two-tailed tests. The SPSS for Windows version 
13.0 statistical software (SPSS Inc., Chicago, IL, USA) was used for all analyses. For 
ANCOVA the general linear model procedure was used. 
3.3. Ethics – Protection of privacy 
For Papers I-IV, approval from the appointed local ethics committee was received 
after reviewing the projects aims, outlining and the ad hoc formulated forms to 
collect patients’ informed consent. Special consideration deserved the ethical 
procedures for the study on self-perceived health status (Paper IV). Before entering 
data into the statistical programs, patients’ first and family names were transformed 
into numeric codes.  
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4. SUMMARY OF THE RESULTS 
The detailed results are presented in each individual paper. 
4.1.  Evidence of spatial clusters of MS in northern Sardinia (Paper I) 
On prevalence day Dec. 31st, 1997 and for each commune we calculated the crude 
MS prevalence rates (per 100,000) with the 95% confidence interval (95%CI) 
obtained by MLE, and the respective rate estimates (per 100,000) with the 95% 
credible interval (95%cI) obtained by Bayesian approach (Table 7).  
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Table 7. Crude rates of MS total prevalence (P) per 100,000 by maximum 
likelihood estimate (ML) and rate estimates by Bayesian approaches. 95%CI: 
confidence interval; 95%cI: credible interval. 
  MLE  Bayesian 
 
  MLE  Bayesian 
Commun
e code   P 95%CI   P 95%cI  
Commun
e code   P 95%CI   P 95%cI 
1   342.5  153.9  760.1   139.3  115.4  167.1  46   98.5  31.8  304.8   143.7  122.6  166.5 
2   100.6  25.2  401.3   124.9  101.6  150.9  47   98.1  72.8  132.3   119.0  100.2  138.2 
3   141.3  109.0  183.1   147.7  127.3  170.2  48   70.9  17.7  283.1   150.5  122.0  181.8 
4   109.3  15.4  771.6   145.3  117.2  179.2  49   207.6  103.9  414.6   138.4  117.7  161.7 
5   0.0  -  -   147.8  124.9  173.1  50   134.9  56.2  323.7   149.5  126.4  171.0 
6   69.0  32.9  144.6   125.2  106.0  148.1  51   186.4  103.3  336.3   156.7  134.4  182.2 
7   0.0  -  -   151.3  125.9  180.9  52   231.0  158.5  336.7   147.6  128.4  169.5 
8   219.5  91.4  526.2   144.7  116.4  175.6  53   0.0  -  -   148.2  120.4  179.6 
9   150.6  62.7  361.3   130.9  107.8  157.8  54   180.7  81.2  401.6   131.1  108.4  158.3 
10   403.2  100.9  1597.5   151.4  128.2  176.7  55   270.9  145.8  502.7   143.0  121.2  166.5 
11   84.5  11.9  597.5   149.4  124.0  174.3  56   235.6  105.9  523.3   141.0  120.5  164.7 
12   126.4  52.6  303.4   144.9  120.3  173.5  57   183.1  95.3  351.5   149.6  126.7  174.3 
13   208.3  108.4  399.9   147.9  126.0  171.0  58   79.5  49.4  127.8   132.7  107.1  161.0 
14   105.7  14.9  746.4   137.8  115.1  163.0  59   254.5  127.3  508.1   151.4  122.4  187.8 
15   0.0  -  -   149.5  122.7  178.6  60   275.9  69.0  1096.1   152.1  127.6  183.8 
16   117.1  16.5  826.3   143.6  116.2  173.5  61   151.1  21.3  1064.2   149.4  122.1  181.6 
17   15.7  2.2  111.0   126.3  106.2  148.6  62   91.4  12.9  645.9   136.9  116.7  159.6 
18   154.7  38.7  616.3   143.5  120.0  169.4  63   72.3  23.3  224.0   132.3  106.9  162.3 
19   0.0  -  -   139.0  112.5  168.8  64   199.3  175.7  226.1   158.6  142.4  175.3 
20   90.3  12.7  638.4   142.7  108.7  184.6  65   65.8  9.3  465.5   138.5  116.5  162.8 
21   190.1  98.9  365.0   129.4  107.4  154.3  66   0.0  -  -   149.7  120.5  186.7 
22   154.3  21.7  1087.0   153.4  128.2  182.0  67   134.8  72.5  250.3   146.6  122.1  172.4 
23   37.6  9.4  150.3   135.3  110.4  163.9  68   180.5  45.1  718.8   150.4  127.8  174.4 
24   193.4  27.2  1359.7   149.7  120.6  181.8  69   91.8  53.3  158.0   140.2  117.0  165.7 
25   153.2  49.4  474.0   145.0  124.4  168.0  70   222.2  156.3  315.8   136.9  119.0  156.5 
26   304.2  114.2  807.6   152.2  127.5  182.0  71   180.2  81.0  400.6   150.6  128.4  175.1 
27   194.7  48.7  775.2   149.4  124.8  175.5  72   413.0  197.0  863.7   162.5  134.5  195.1 
28   0.0  -  -   141.9  109.2  180.5  73   92.8  13.1  655.5   148.7  124.5  177.8 
29   124.7  31.2  497.1   153.0  127.9  178.8  74   199.3  74.8  529.8   137.8  110.8  167.5 
30   273.2  68.3  1085.7   149.5  125.2  178.9  75   59.6  8.4  422.0   140.2  116.8  164.9 
31   0.0  -  -   143.1  114.5  179.7  76   129.2  48.5  343.7   153.9  131.7  180.4 
32   335.0  83.8  1329.3   149.0  120.3  180.2  77   131.5  54.7  315.5   156.6  131.3  181.5 
33   172.5  105.7  281.5   153.6  133.6  176.4  78   37.3  5.3  264.6   148.6  124.1  174.0 
34   92.1  13.0  650.6   140.9  116.1  168.4  79   54.1  13.5  215.9   134.4  109.4  160.7 
35   117.1  68.0  201.5   126.3  99.7  157.2  80   99.0  24.8  395.0   124.0  100.2  150.5 
36   159.4  51.4  493.0   132.9  109.3  161.9  81   54.0  7.6  382.1   134.9 4,5  166.5 
37   181.0  75.3  434.0   131.5  108.0  159.8  82   0.0  -  -   135.4  113.1  161.4 
38   0.0  -  -   148.1  116.7  184.9  83   191.8  72.0  509.8   123.6  89.1  167.5 
39   147.9  20.8  1042.3   143.4  117.0  172.4  84   45.3  6.4  320.6   121.7  96.5  150.3 
40   0.0  -  -   148.6  116.4  185.1  85   0.0  -  -   124.6  102.0  149.2 
41   0.0  -  -   123.3  102.0  147.8  86   171.8  24.2  1209.2   142.6  120.2  169.3 
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42   140.7  45.4  435.4   148.4  125.8  173.3  87   0.0  -  -   136.6  114.2  161.7 
43   128.9  18.1  908.9   154.4  128.2  182.2  88   123.6  17.4  872.0   142.2  118.5  168.1 
44   365.0  137.0  968.3   147.3  124.2  172.9  89   76.6  10.8  541.5   144.0  112.6  179.3 
45   119.0  29.8  474.7   144.1  110.7  187.1                    
          total  149.1 138.3 160.7  142.5   
 
 
On prevalence day, 686 MS cases (492 women and 194 men) were living in the 
province of Sassari. The total crude prevalence rate was 149.1 (95%CI, 138.3-160.7), 
211.2 (95%CI, 193.4-230.7) for women and 85.4 (95%CI, 74.2-98.3) for men. The 
overall standardised rate was 142.9, 204.0 for women and 81.8 for men. The crude 
prevalence rates ranged between 0 and 413.0 (95%CI, 197.0-863.7) for both genders 
and between 0 and 743.5 (95%CI, 186.0-2922.7) for women.   
The overall Bayesian estimates ranged between 119.0 (95%cI, 100.2-138.2) and 
162.5 (95%cI, 134.5-195.1) with a mean value of 142.5±5. Among women the mean 
value was 204.9±11.6, ranging between 178.4 (95%cI, 149.9-209.5) and 228.0 
(95%cI, 184.9-277.2). 
The total standardised prevalence rates obtained for each of the 89 communes on 
prevalence day by MLE and Bayesian approaches with different cut-off points, and 
the distribution of PP values for total cases was mapped for the province of Sassari. 
Bayesian estimates and their respective PP values were also calculated and mapped 
based on the commune of residence at patients’ 5-15 years of age 
While it is not possible to identify peculiar spatial aggregates by observing the total 
standardised prevalence rates map due to the high variation, a clustering pattern in the 
west of the province and a west-to-east gradient appeared to be fairly evident when 
mapping the Bayesian estimates. In particular, 17 communes out of 89 had a 
Bayesian estimated prevalence of 150 per 100,000 and above, i.e., higher then the 
province standardised average rate. However, only 3 communes, i.e., Sassari, Ossi 
and Tissi (Sassarese sub-area) had a PP higher than 90% and are therefore considered 
“hot areas”, whereas for the remaining 14 communes only an indication for a higher 
risk could be given. In the eastern province, prevalence was lower for eight 
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communes. The map estimates of prevalence rates by commune of residence at age 5-
15 years showed a different spatial aggregation in the province. A large proportion of 
the communes located in the western province (Sassarese, Southern and Northern 
Logudorese, i.e., sub-areas 1, 3, 5) showed a spatial cluster of MS with a probability 
of 75-90%.   
4.2. Incidence trends of MS in northern Sardinia and change of clinical 
phenotype over time (Paper II) 
A total of 689 patients with onset of disease from 1965 to 1999 within the province of 
Sassari were included in the analyses: 496 women and 193 men, giving a female–
male ratio of 2.6 (Figure 4). 
 
Figure 4. Distribution of the MS population by age of onset and gender. 
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The mean annual crude incidence rate for the whole province was 4.6 per 100,000: 
6.5 for women and 2.6 for men (woman–man ratio of 2.6). The overall age-adjusted 
incidence rate was 4.4. The age-adjusted incidence rate increased markedly and 
significantly from 1.1 per 100,000 population in 1965–69 and 2.2 in 1970–74 to 
about 6 for the last three 5-year periods, 1985 to 1999. The trend did not differ 
significantly between genders during the study period. 
The crude incidence rate differed significantly between the linguistic areas during the 
whole study period (p = 0.02, chi-square test), with Sassarese showing the highest 
rate of 5.4 and the Eastern and Southern Logudorese and Goceano areas with the 
lowest rate of 3.8. The incidence increased over time in all areas, and this time trend 
did not differ significantly.  
The clinical course at onset was retrospectively evaluated for 635 cases, 512 (81%) 
with RR and 123 patients with a progressive course at onset. There was a 
significantly higher increasing trend among the group with RR course at onset than 
among those with progressive one (p < 0.001, chi-square test), with an increase for 
the former from 61% during 1965–79 to 90% during 1985–99. 
The most frequent symptoms at onset were sensory (40% of the patients), pyramidal 
(22%) and visual manifestations (22%). The distribution of manifestations at onset 
did not differ significantly in the overall incidence interval. 
The mean age at onset for the whole study period was 28.6 years (95%CIs: 27.9–
29.2), with no significant difference between men and women, and between patients 
with initial RR course and those with initial progressive course. A late onset (45 years 
and older) was registered for 4.8% of the whole study population. 
The mean age at onset increased steadily and significantly from 25.7 years in 1965–
69 to 30.6 years in 1995–99. Since age at onset and clinical course are related and 
since the distribution of both these clinical variables changed over time, we 
performed an analysis of variance with age at onset as the dependent variable and 
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time period (using the seven 5-year intervals) and course of disease as fixed factors. 
Since the shift towards more cases with initial relapsing course during the last periods 
is expected to be associated with a lower age at onset, the estimated increase in age at 
onset over time was even more marked after adjusting for type of initial clinical 
course. Likewise, the effect of initial course on age at onset was statistically 
significant in this model, with an estimated difference of 2.6 years as compared with 
the observed difference of 1.3 years between patients with progressive onset and 
patients with relapsing onset.  
The time lag between clinical onset and diagnosis decreased significantly from 13.0 
years in 1965–69 to 0.9 years in 1995–99. 
4.3. Early childhood is the age of MS induction period in northern Sardinia 
(Paper III) 
The analysis included 649 MS patients with information on changes in municipality 
of residence up to at least age 15 years.The analyses using temporal closeness of 1, 2 
and 5 years all showed space-time clustering in early childhood. For the 2-year 
temporal closeness, statistically significant clustering was observed from age 1 to 3 
years; clustering peaked at age 1, with a ratio between observed and expected close 
pairs of 1.08 and an empirical p value of 0.039. The strength of the clustering was 
only slightly less for the other cut points for temporal closeness, with peaks at age 1 
year (observed-to-expected ratio = 1.08) for 1-year closeness and age 3 years 
(observed-to-expected ratio = 1.07) for 5-year closeness. 
Subgroups were also analysed according to clinical characteristics (age at onset, 
initial clinical course and year of clinical onset) and demographic variables (gender, 
year of birth and geographic sub-areas). All these were analysed using 2-year 
temporal closeness and clustering at age 1 year. Clustering was significantly 
increased for women, patients with RR course at onset, patients with recent onset 
(after year 1982) and patients living in the eastern province (sub-areas 2, 4, 5, 6). 
Clustering was borderline significant for patients born after 1959 and patients with 
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age of onset <30 years, while it was increased but not statistically significant for men 
and for patients living in the western province (sub-areas 1, 3, 22).  
The cluster cases had an earlier mean (SD) age of onset of 27.3 (7.8) years versus 
30.3 (10.2) years for the non-cluster cases (p = 0.0005, t-test). The significant 
difference in the standard deviation (p < 0.0001), Levene’s test for equality of 
variance) indicates a more uniform epidemiological pattern in the age of onset among 
the cluster patients. 
Performing the analysis backwards by a fixed period prior to onset failed to show any 
clustering. The degree of clustering tended to be lower than expected, though non-
significantly. 
4.4. Poor subjective scoring of health status in patients with non to mild MS at 
EDSS (Paper IV) 
The study was conducted on 203 patients (156 women and 47 men) who gave 
consent to participation (93% of the total). They underwent clinical neurological 
examination and the RCPM test. A total of 197 patients (150 women and 47 men, 
woman-man ratio: 3.2) scored a corresponding IQ > 69 on the RCPM test and were 
thus administered the SF-36 questionnaire and considered for statistical analysis. The 
mean age was 41.3 years and the mean EDSS was 2.2.  
SF-36 was completed thoroughly by 183 (93%) patients. Of 6,895 items (197 times 
35), 66 were missing (1.0%). Substitution could be performed for 41 (0.6%) of these 
items. 
All mean subscale scores for MS patients were significantly reduced, except for 
bodily pain. The mean score for physical functioning was especially reduced, almost 
one SD below the mean score for the general population. Mean scores of male and 
female MS patients did not differ significantly. 
Mean standardised SF-36 subscale scores were also analysed for a subgroup of 105 
patients (79 women and 26 men) with EDSS 2.0: “minimal disability in one 
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functional system”. They were also significantly lower than in the general population, 
except for bodily pain and mental health. 
Mean scores of male and female MS patients did not differ significantly. 
The correlation between EDSS and the physical functioning subscale in the total MS 
sample was rather low (Pearson correlation coefficient = –0.14, p = 0.05), with EDSS 
explaining only 2.0% of the variation in the physical functioning subscale. EDSS also 
correlated, though poorly, with role–physical, general health and vitality (correlation 
coefficients of –0.17, –0.19 and –0.17, respectively). EDSS did not correlate 
significantly with the other SF-36 subscales. Neither disease course nor disease 
duration correlated significantly with any SF-36 subscale. 
Benzodiazepines and antidepressants were assumed by 24 (14.2%) patients as 
symptomatic treatment. No main effect of such therapies was found on the SF-36 
subscales, adjusting for EDSS scores and disease duration (data not shown). 
Running regression analyses with the physical functioning subscale as the 
independent variable and each of the other 7 subscales as the dependent variable 
showed significantly smaller regression coefficients among the MS patients 
compared with the general population for all subscales except for role–physical and 
social functioning. Among men, the regression coefficient was significantly lower for 
general health among MS patients compared with the general population, whereas the 
other subscales did not differ. Among women, the MS patients had a significantly 
lower regression coefficient for all SF-36 subscales except for role–physical and 
social functioning. 
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5. GENERAL DISCUSSION 
5.1. Main findings  
 5.1.1. Heterogenous spatial distribution of MS in northern Sardinia 
The results of the spatial cluster analysis by means of Bayesian approach reported in 
Paper I have allowed a geographical mapping of the disease prevalence in the 
province of Sassari, northern Sardinia. Due to a negligible population migration in- 
and out-flow even between adjacent Sardinian communes, mapping the disease 
distribution of prevalent cases may yield good estimates of possible spatial clustering 
of MS.159 
Mapping the distribution of Bayesian estimates for total cases by commune of 
residence on prevalence day disclosed a clustering pattern of MS in the western 
province, with special regards to three communes in the Sassarese sub-area. Further, 
a west-to-east gradient was observed. In the eastern province, prevalence was lower 
for eight communes. The map estimates of prevalence rates by commune of residence 
at age 5-15 years showed that for a large proportion of the communes located in the 
western province (Sassarese, Southern and Northern Logudorese, i.e., sub-areas 1, 3, 
5), prevalence was high but only an indication for a spatial clustering was given. 
A considerable number of spatial cluster studies are reported in the literature. 
However, the great majority consist of post-hoc analyses, driven by the attempt to 
rule out an association between disease and one or more possible risk factor(s) within 
an observed or believed “hot spot” of disease. Paper I is a spatial a priori cluster 
analysis of MS distribution in northern Sardinia. As opposed to post-hoc cluster 
analysis, it is therefore supported by hypothesis, is carried out in a population with no 
previous evidence of clusters and is thus less subject to bias.54,60  
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A previous epidemiological population-based survey confirmed that Sardinians are at 
high risk for developing MS.123 The reported onset-adjusted prevalence rate of 149.7 
per 100,000 reflected the overall province mean prevalence rate, and no conclusions 
could be drawn on the presence of possible true “excesses” or “lacks” of MS cases in 
the study area, which would instead represent valid clues to either risk or protective 
factors.  
A Bayesian approach was adopted to investigate the spatial variation of MS 
prevalence and to overcome the difficulties of traditional methods of mapping disease 
risk.191 Although the maps obtained by means of Bayesian approach are only a 
representation of the true disease risks in the area and can therefore reflect artifacts 
deriving from potential confounding spatial effects,192 this method best reflects the 
disease spatial variation in small areas at low population density. Bayesian disease 
mapping models are conservative with high specificity, but have a low sensitivity, 
especially in the raised risk-areas having only a moderate excess.193 Confounders can 
be due to autocorrelation, or the choice of a prior distribution that will affect posterior 
inferences. To assign the model the proper prior, the key part of the Bayesian 
approach (see Section 1.4.1), a sensitivity analysis was performed on non 
informative, moderately and highly informative priors.70,194,195 These results do not 
actually yield exact and recommended models, but rather allow one to rule out those 
that are less informative for epidemiological purposes. The “subjective” choice of our 
prior distribution therefore best reflected our knowledge on the phenomenon under 
study.  
The prevalence-based place of residence may not necessarily reflect the place of 
putative MS acquisition and/or exposure to possible risk factors. However, because of 
the negligible migration rate into or out of the province, or even between adjacent 
communes,159 mapping the distribution of prevalent cases may still yield good 
estimates of possible clusters. Further, spatial clusters of MS were searched for also 
by mapping the distribution of cases by commune of residence at age 5 to 15 years, 
which has been previously indicated as the putative age of MS acquisition.44 This 
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analysis was likely to be more reliable and informative, because the place of 
residence during such age may be associated to exposure to the putative exogenous 
(environmental) risk factors inducing MS. Further, when searching for etiological 
clues, and given specific assumptions, spatial aggregates based on residence during 
adolescence could reflect the exposure to causative exogenous factors particularly 
concentrated in some sub-areas, or the population’s predisposing genetic background 
secondary to different allelic concentrations at microgeographic level especially 
found in innermost villages and rural close communities. Interestingly, an indication 
for spatial clustering for prevalence at age 5-15 was found for parts of sub-areas 1, 3 
and 5 which are characterised more by close communities.163 Of note, this area 
borders with the commune of Macomer (province of Nuoro), where MS was reported 
as having occurred as epidemic in the 1950s.111 This incidence study indicated that no 
MS cases were detected until early 1950s, and that 13 cases had clinical onset in the 
years 1952-1981, when the average annual incidence was 4.8 per 100,000. Incidence 
peaked between 1957 and 1961 with 10.2 per 100,000 and slowly decreased again up 
to early 1980s. The authors hypothesised an epidemic of MS triggered by exogenous 
factors introduced by a population from mainland population migrated into a 
Sardinian ‘naïve’ population after the end of World War II.  
A space clustering study on MS was conducted in the province of Nuoro, central 
Sardinia, by Montomoli et al.65 Similarly to our work, prevalence rates and Bayesian 
estimates were mapped across 100 communes. As compared to the province mean 
prevalence rate of 157 per 100,000 in 1998, and based on PP mapping, spatial 
clustering was found for the communes of Nuoro, Oliena, Fonni and Desulo, that is in 
the Nuorese and Barbagia sub-areas located in the very inner province territory. 
Interestingly, an indication for a spatial aggregate was found in communes bordering 
with the province of Sassari and especially with those participating to the spatial 
cluster for age 5-15 years reported in Paper I (southern Logudorese). Based on 
previously reported evidences on genetic heterogeneity at microgeographic level161 
and on the “high number of multiplex families” assessed, the authors concluded for 
the genetic nature of such spatial cluster. 
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Clustering of MS was searched with a large population-based survey in the Tayside 
region of Scotland for the period 1970-97.196 The study was conducted by means of 
spatial scan statistic without a priori specification of the size or location (temporal or 
spatial) of potential clusters, and capture-recapture methods to test the hypothesis that 
clusters may be detected due to improved ascertainment either temporally or 
geographically. The spatial scan analysis identified two clusters. The most likely 
cluster was exclusively temporal, between 1982 and 1995 with an annual incidence of 
8.6 per 100 000 per year. There was also a significant secondary temporal/spatial 
cluster for the period 1993-95 for a mostly rural area to the south-west of Perth. The 
cyclical nature and close temporal proximity of the peaks argues against a purely 
genetic component. Furthermore, the population studied is ancestrally fairly 
homogeneous, with low migration rate and stable Scottish ethnicity in over 90% of 
individuals. Similarly to our setting, it was suggested that in the Scottish population 
where genetically based susceptibility to MS is generally high, other environmental 
factors become important in modulating the frequency of MS. The spatial cluster was 
detected in a rural area, at plausible increased genetic susceptibility genes. However, 
the cluster for this area occurred during a specific two-year period lends support to 
the relevance of environmental factors. The study design and the statistical 
methodology used argued against overascertainment of clusters or confounding. 
However, whether prevalence-based spatial clustering reflects the predominant role 
of genetic rather than environmental factors in determining the disease is a difficult 
question, given the cross-sectional nature of the study design. As MS is clearly not a 
single source infectious disease, spatial cluster studies may help test the hypothesis 
that a widely and evenly spread infectious agent may produce disease in subgroups of 
genetically more susceptible individuals. Therefore, if the identified cluster were 
genetically determined, i.e., located in an area at high inbreeding rate, a disease mode 
of inheritance could instead be better investigated. In this perspective, despite 
evidence based on the geographic distribution of blood groups and HLA gene 
frequencies96,97,160 and human Y chromosome polymorphisms197,198 that Sardinians 
are genetically homogeneous and distinct, as compared to the rest of Caucasians, a 
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certain degree of genetic heterogeneity, possibly due to different inbreeding rates at 
microgeographic level, has been highlighted by analyzing the variability of 
mitochondrial DNA polymorphisms in two different Sardinian samples.164 
We can speculate that the distribution of prevalence reflects the distribution of 
disease risk factors, based on the evidence that Sardinians are a steady population. 
However, other factors (e.g., socio-economic and health care related) may confound 
our results and should be adjusted for with further analysis. 
Microgeographic heterogeneity of disease spatial distribution may potentially depend 
on differential case ascertainment. However, because of the methodology adopted for 
case ascertainment, fulfilling a “spider” type of approach,168 we were rather confident 
in ruling out bias due to differential case ascertainment across the province sub-areas.  
In Paper I we concluded that an indication for the action of an exogenous factor in 
some sub-areas and during adolescence was given with the spatial analysis of 
prevalence rates. This evidence could serve for ecological studies purposes,199 i.e., 
correlational investigations with the spatial distribution of the disease putative risk 
factors. Nevertheless, incidence-based space-time clustering studies or an analysis of 
incidence trends over a defined time interval would be more informative in 
etiological research. 
 5.1.2. Incidence temporal trends in northern Sardinia 
With Paper II we fulfilled one of the implications for further studies underlined in 
Paper I, i.e., a population-based incidence study of MS in the same Sardinian 
population. We showed a remarkable increase of the disease occurrence since 1965 to 
1999 which explained the increased MS prevalence in time previously observed.116,123 
The incidence rate is not in general influenced by improved survival, and if based on 
the disease clinical onset – as in Paper II - and not on the diagnosis, the reduced time 
lag between clinical onset and diagnosis indicating an intensified case-finding over 
time, cannot be source of biased increased incidence. The patients diagnosed in more 
recent periods would still have been assigned their true year of clinical onset. 
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Improved case-ascertainment can only influence incidence if patients in the early 
periods had died before being diagnosed. However, this is unlikely to have occurred 
in our study due to the general low mortality rate of the disease, and to the multiple 
assessments conducted arguing against inaccurate registry.  
Improvement of diagnostic accuracy could be responsible for earlier diagnosis and 
subsequent registration of a greater number of cases. Nevertheless, when comparing 
Sardinian data with those from a northern Italian health district with easier access to 
MS-specific diagnostic facilities (e.g., MRI), the temporal trend of the time lag 
elapsing from clinical onset to diagnosis and the sensitivity to diagnose mild cases 
based on EDSS were close to parallel in both settings.110,123,200 Despite the similar 
degree of case ascertainment, however, a steady increase in incidence rates was 
observed only in Sardinians starting in the 1970s, thus pointing to a corresponding 
change in the distribution of true risk factors.  
Incidence rates appeared to be stable on high values during the last three 5-year 
periods, i.e., 1985-99. Nevertheless, because incidence studies are conducted on 
patients who have already received a diagnosis, true incidence rates from the more 
recent period are likely to be underestimated given that some patients have not yet 
received a diagnosis in relation to features intrinsic to the disease course.201  
In our study, clinical characteristics at disease onset deviated in two ways from an 
evenly distributed increase of incidence rates. Firstly, the increase over time mainly 
applied to patients with a RR course at onset. This can be ascribed to recall bias 
because patients from the study most remote cohorts may fail to remember, allocate 
in the correct time and report their first episode(s), and do instead remember the time 
that the disease grew severe. Some of these patients may therefore potentially be 
misclassified as having had a progressive onset. Nevertheless, had this bias occurred 
in our study, age at onset for these cases would have also been affected towards 
higher estimates. Instead, age at onset was significantly lower for the most remote 
cases. 
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Regardless of initial clinical course, and due to the retrospective nature of the survey, 
a bias toward identifying symptoms as attributable to MS might have been 
introduced, again especially for the cases in the earliest part of the study period. 
Should vague symptoms at onset be missed for these patients, then the estimated date 
of onset would have been later than the true one. Again, the lower age at onset for 
these cases does not argue for such a bias, and rather points to accurate ascertainment. 
In support to this statement and in favour of good validity of our data, is also the fact 
the information on the older cohorts patients were registered at time of these patients’ 
respective diagnosis (possibly 20 or 30 years before the study started) and not at the 
time of the present study. With this respect, data collection rather followed a 
prospective design, although a case review was retrospectively performed for the 
study purposes. 
A significant finding was, in fact, the younger age at disease onset for the first time 
intervals and its increasing trend over the whole study period. As a higher age at 
onset has been reported for patients with initial progressive course,202-205 we 
performed an analysis of variance on age at onset to adjust for initial course.We 
found that if the distribution of type of initial course had been stable over time, such 
increase of age at onset would have been even stronger. This further argues against a 
change of initial course over time due to recall bias and rather points to a change of 
the MS clinical phenotype over time and maybe to changes in underlying disease 
determinants.  
A higher age at onset in recent cohorts of a population at high risk for the disease 
such as Sardinians is in contrast with previous evidences of age at onset varying 
according to the disease prevalence, and being lower in countries with high 
occurrence.206 
Despite the wealth of studies on MS incidence temporal patterns, the trend of age of 
onset is seldom discussed. Observations are not univocal. In a population- and 
registry-based study on spatial and temporal clustering in the Tayside region of 
Scotland for the period 1970-97, the mean age of onset was 35.7 years and appeared 
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to increase from 33.2  in 1970-79 to 38.1 in 1990-97.196 The mean age at onset 
remained quite stable over time, ranging from 32.8 years in 1953-62 to 31.7 in 1973-
82, in a study conducted in western Norway (Hordaland County) which showed an 
increase of the annual mean incidence rate from 2 per 100,000 in 1953-62 to 4 in 
1968-77.207 Repeated assessments conducted years later in the same population 
confirmed increasing incidence rates for the period 1958-87, with 5 per 100,000 in 
1978-82, and showed a fluctuation of the age of onset.208 Its mean was 35.6 years for 
the period 1953-57, followed by a significant decrease to 30.4 years in 1963-67 and 
tendency for an increase up to 34.4 years in the period 1983-87. No significant 
difference in age of onset was instead reported for another population in western 
Norway (Møre and Romsdal County) (29.7 years in 1961 versus 30.3 in 1985), in 
which a similar increase to Hordaland County in incidence in comparable time was 
also observed.209 
Our results on age of onset were in contrast with a study conducted in another 
Sardinian MS population which had shown an anticipation of the age at onset, from a 
mean of 41 years for patients born between 1913 and 1939 to a mean of 22 years for 
those born after 1970.210 However, the study was not population-based since it 
included consecutive patients referred to a clinic from an undefined area of the island. 
It is therefore likely that a selection bias was introduced by excluding patients with 
very benign or very severe MS, as it is often observed in hospital-based series. 
Furthermore, in the absence of a long maintained registry system and multiple 
assessments over time, the patients’ date of onset was estimated only at the time of 
the mentioned study, thus challenging the validity of these estimates for the oldest 
cohorts. As already explained, by failing to report the first episode, estimates for age 
at onset are biased towards older age and obviously especially for most remote 
cohorts. Lastly, the analysis was performed by decade of birth (<1940, 1940-49, to 
>1970) leading to an underestimation of age at onset for the youngest cohorts in 
which a later onset of MS may have not occurred yet. The authors made some kind of 
adjustment for this, but failed to present more reliable data, e.g. by analysing the data 
according to time-periods rather than birth cohorts.  
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In our study, the incidence rates differed significantly between the province sub-
areas. The westernmost areas (Sassarese, Northern Logudorese and Algherese) had 
higher mean rates than the easternmost ones, with some overlapping to what observed 
with the spatial cluster analysis in Paper I. This further strengthens the hypothesis 
that the heterogeneous distribution of MS cases at microgeographic level reflects a 
true different risk distribution in these sub-areas. As with Paper I, because of the 
survey methodology adopted for this study study, we feel reasonably confident in 
ruling out that different rates in urban versus rural areas, as well as in the western 
versus eastern sub-areas of the province, are due to biased case ascertainment.  
Despite such spatial difference in the incidence rate distribution, an almost parallel 
increasing trend was observed in time for all sub-areas. It can be speculated that 
differences in incidence absolute rates could reflect a genetically-based predisposition 
to the disease, or different gene–environment interaction effects at microgeographic 
level. The action of an exogenous factor whose concentration has increased over time 
could nevertheless explain the increasing occurrence in disease over time.   
Steadily increasing incidence rates in Sardinians over comparable periods of time 
have also been reported for juvenile diabetes (IDDM).211,212 Sardinian IDDM has 
been shown to share specific immunogenetic features with Sardinian MS, such as 
HLA haplotypes DRB1*0301-DQA1*0501-DQB1*0201.213 In a study by Songini et 
al,211 improved survival rates, reduced stillbirth, perinatal and first-year mortality 
rate, a more accurate case ascertainment and emigration could not explain IDDM 
incremental trends in Sardinia. The rather homogeneous geographical distribution of 
the high IDDM incidence rates throughout the island, coupled with the marked 
general increase in their temporal trends rather pointed to the action of an 
environmental factor uniformly distributed in the territory that had rather recently 
changed its exertion.212  
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5.1.3. Space-time clustering in northern Sardinia 
Based on the evidences of a heterogenous spatial distribution of MS at 
microgeographic level defined by the province sub-areas, and of a significant 
increase in the disease occurrence in a relatively short time period (little over than a 
generation time span), with Paper I and Paper II we argued in favour of the 
predominant role of exogenous factors in determining MS in Sardinians.  
With Paper III we meant to use a different methodological approach to explore the 
presence and action of an exogenous factor(s) inducing MS in the same Sardinian 
population and over the same time period. Furthermore, we aimed at disclosing the 
age at which individuals that later developed MS might have shared common 
exposures, and thus at identifying a putative induction period to Sardinian MS. 
Lastly, we were interested in investigating whether such exposure(s) was associated 
with demographic and/or clinical variables, and might account differently in different 
disease phenotypes. 
In order to fulfil this, we used a space-time cluster analysis of incidence data in the 
province of Sassari (see Section 1.4.3.). The idea behind this type of analysis is that 
an excess of clustering both in space and in time reflects the role of an exogeneous 
agent that varies in intensity between areas. The most intuitive such agent would be 
infectious.  
The analysis disclosed patterns of space-time clustering, and these were significant at 
age 1 to 3 years, suggesting that early childhood is the induction period of MS in 
Sardinians. Furthermore, clustering was most marked in women, in patients with 
more recent onset (after 1982), with RR initial course and for sub-areas 2, 4, 5 and 6 
of the province of Sassari.  
Confounding demographic factors specifically influencing the sub-areas were 
reasonably ruled out. In fact, if the general population had substantially migrated 
across the province, it would have been towards the major urban area (Sassarese), 
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yielding more substantial clustering in the western sub-area and thus biasing the 
results in the opposite direction as compared to what observed.  
With regards to putative age periods for MS susceptibility, two periods of 0 to 5 years 
and 10 to 15 years were suggested using stochastic models estimating the distribution 
and thus the length of the latency period for MS.37,55 Despite the latter of these 
periods was suggested as the most plausible one, our evidences are in line with the 
estimated younger period. Wolfson et al. suggested that the mean latency period in 
their population was 18 years based on 10 to 15 years of age period. According to our 
data the estimated duration of the latency period could be over 25 years. 
That early childhood might comprise the disease induction period is in agreement 
with other recent evidences obtained with very different study designs and 
methodological approaches. The relative contribution of ancestry, country of birth 
and residence in determining MS risk and age of MS onset was studied by Kennedy 
et al214 in a population of 44 pediatric and 573 adult MS patients residing in Ontario, 
Canada. The authors concluded that the place of residence during childhood, 
irrespective of ancestry, was the major demographic determinant for lifetime risk, 
suggesting a predominant influence of environment in MS risk. They also found that 
individuals with ancestors originating from regions at low risk for MS and raised in a 
region of high MS prevalence, had an earlier age of MS onset. This evidence and ours 
based on a tendency for space-time clustering in individuals that would later manifest 
MS at an earlier age, seem to suggest a role of exogenous factors in the disease 
phenotypic expression and argue in favour of heterogenous etiopathogenetic 
mechanisms. 
A climate-related interaction between genes and environment during gestation or 
shortly after birth has been hypothesised to trigger MS at least in northern Caucasian 
populations from the observed excess of spring births in MS patients.29-31 Pooled 
analysis of datasets from Canada, Great Britain, Denmark and Sweden (n = 42,045) 
showed that fewer (8.5%) people with MS were born in November and more (9.1%) 
were born in May.  
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A large longitudinal population-based study aimed at investigating incidence changes 
by analysing women-men gender ratio over time, by year of birth and in a cohort of 
27,074 Canadian patients, showed a markedly significant increased of MS in women 
as compared to men over at least 50 years.215 According to the authors, this rapid 
change must have environmental origins acting in individuals’ early life, even if it is 
associated with a gene-environment interaction, and implies that a large proportion of 
MS cases may be preventable in situ.  
In contrast, no space-time clustering around birth was found among 783 patients in 
Northern Ireland216 or among 556 patients in the Netherlands.217 However, residence 
at birth might not necessarily reflect the actual residence during disease initiation 
even in apparently stable populations. Another space-time clustering study conducted 
on two Dutch populations (Groningen and Rotterdam) with three different statistical 
methods, and based on prevalence at birth failed to disclose clustering patterns in 
both areas and for methodological approaches used.217 The authors concluded that 
perinatal infectious events are unlikely to be relevant factors in determining the 
disease initiation. 
A period of susceptibility to MS between birth and adolescence was indicated with 
migration studies.40,45,47,218 These studies, however, can be easily biased by selection 
of the migrating population, small sample sizes and the difficulty in assessing the 
time elapsing from migration to disease onset. Further, too few studies have 
investigated the age at migration among migrants from low- to high-prevalence 
countries to provide further evidence.37  
A formal cluster analysis of MS in space and time was carried out in a region of 
western Norway in a population of nearly 400,000 in the early 1980s when 
prevalence was 75.5 per 100,000, and the mean annual incidence rate for the previous 
20 years was 3.7 per 100,000.219 No significant space-time clustering was found, but 
only an indication for clustering according to year of onset the rural part of the study 
area.  
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A few years later another space-time clustering analysis was performed in the same 
population, including patients with an onset of disease between 1953 and 1987, and 
by means of a different statistical model (the generalised regression approach of 
Mantel).169 Significant clustering was observed between age 13 and 20 years, with a 
marked peak at age 18. At this peaking age, an analysis by subgroups of patients 
according to clinical and demographic variables showed significant clustering in 
women, in patients with RR initial course and in more recent cases.  
In this Norwegian population, space-time clustering was found at different ages as 
compared to our results suggesting a population-specific difference in the disease 
putative initiation. Nevertheless, clustering was found in the same subgroups of 
patients by clinical and demographic variables, which might instead point to a greater 
susceptibility to the exogeneous factor in these sub-groups. 
A further study of this material correlated a high degree of clustering with early age 
at onset and the female gender.170 The most clustered patients’ age at onset was on 
average 5 years lower than the least clustered patients’. The authors interpreted this as 
an evidence of shorter latency for the patients with strong clustering (i.e., different 
etiological agent), or that these cases were exposed to the agent at an earlier age. 
Interestingly, as in our study, a greater variation of age at onset was found for the 
Norwegian non-clustered cases, suggesting greater heterogeneity in the latent period 
duration for these patients, possibly due to the role of multiple agents of different 
nature. The more likely infectious nature of MS in clustered patients tending to 
develop the disease at an earlier age is in agreement with “the pubertal hypothesis” 
within the Faroes MS epidemics.220 According to this hypothesis, the putative disease 
initiation at puberty was believed to be triggered by a viral infection, appeared to be 
strong candidate for earlier age of disease onset. 
Space-time clustering was marked in the eastern province. In this work, this area 
comprised Southern Logudorese (sub-areas 5) which was part of the spatial clustering 
based on residence at age 5-15 years reported in Paper I.  
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Our study and others169 have detected no space-time clustering patterns reflecting 
fixed latency periods. This argues against the hypothesis that the disease is caused by 
infection from MS-specific viral agents with fixed incubation time intervals, but 
rather, by more complex mechanisms and interactions occurring in early childhood. 
In a space-time clustering study conducted over 42 and 29 cases in the Orkneys and 
Shetland Islands respectively,221 probably due to the small population, no clustering 
was found using residence at different ages. However, as opposed to the Norwegian 
study169 and our work results, a bimodal pattern of clustering was found at a fixed 
latency period of 21-23 years, and just before clinical onset. The authors 
hypothesised the action of a “MS-specific” exogenous (viral?) agent with a fixed long 
two-stage incubation period. 
Our findings intuitively lend support to the existence of an infectious agent acting as 
a risk factor for MS in Sardinia during early childhood. An alternative hypothesis 
would be that space-time clustering at a certain age reflected instead a non-exposure 
to factors to which individuals are normally exposed, and that would protect the 
population from developing the disease. The “polio hypothesis” by Poskanzer et al222  
and later supported by Alter et al223 suggested that the hypothesised agent causing 
MS is ubiquitously distributed and circulates in populations with low MS incidence, 
and, conversely, that infections with the same agent later in life may instead increase 
the risk of MS. Cooke posed a similar hypothesis in a critique to the “pubertal 
hypothesis” of the Faroe Islands epidemics.49  
MS epidemics in the Faroe Islands was reported by Kurtzke112 after World War II  
and believed to be have been caused by exposure from one source that triggered the 
onset at about 11 years of age in a population that was virgin to that specific exposure 
(“pubertal hypothesis”). The clinically overt disease would develop after a fixed 
latency period. Reanalysing the Faroese data Cooke suggested instead that the 
increased risk of MS was subsequent to the lack of a highly contagious infection from 
a widespread (viral) agent that should have taken place before age 3 years conferring 
protection against MS (“protective hypothesis”). This is in agreement also with the 
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higher risk of MS found among individuals with late onset of the typical childhood 
infectious diseases, such as infectious mononucleosis, mumps and measles.224,225 
Furthermore, it has been shown that exposure, within age 6 years, to an infant sibling 
is associated with a reduced risk of MS, likely in relation to the high rate of childhood 
infections among infants.226  
Furthermore, Cooke underlined the importance of the population immunitary 
background in the disease determination, which can change depending on whether 
individuals are virgin to newly introduced exogenous (viral) factors, as in the 
remoteness of Faroe Islands, or on whether they have already been immunised to 
multiple infections, as for open and populous regions. With respect, the early age of 
disease initiation within the “protective hypothesis” would not clash with the older 
one suggested with migration studies.   
As for our evidences, the question arises as to what kind of background immunity 
characterises Sardinians, or at least the eastern subpopulation in which clusters were 
detected, and whether the “protective hypothesis” could apply to our study population 
as well. In this scenario, our cluster cases might have been unexposed to any of the 
common infectious diseases in early childhood due to either the absence of the 
causative agents in those years or areas, or to conditions protecting them. Based on 
these assumptioms, it is difficult to completely disregard the hypothetical role of 
newly introduced childhood vaccination programs (e.g., against measles, hepatitis 
virus B, influenza) in triggering the disease by means of “protecting” individuals 
from common childhood infections, despite meta-analytical studies have failed to 
report associations between the disease onset or reexacerbation and vaccines.27 
Space-time clustering studies have some limitations which are intrinsic to the 
statistical model and some limitations in relation with the use in MS.54 In general, 
these models have usually low statistical power of the tests, with special concern to 
rare conditions. Also, since observations are pairs and not single individuals, the 
structural dependence between the observations makes it difficult to apply the correct 
method to calculate p values. Due to a complicated theoretical distribution of the test 
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statistic based on these observations, only approximate methods can be used. Lastly, 
these models are depending on assumptions, whose nature can influence the 
conclusions reached about the characteristics of the latency period, such as its 
duration or the age of susceptibility, especially in a disease for which there are no or 
just few concrete leads of its etiology.227 
As for the use in MS, while the use of space-time cluster analysis is especially 
indicated for diseases caused by a single-source infectious agent, there is little 
evidence that MS is caused by an agent with such characteristics. The disease 
causative agent is rather hypothesised to be commonly widespread and to interplay 
with other factors, including the genetically based trait and demographic features. 
This multifactorial etiological pattern might mask a space-time clustering effect, and 
confer the test a low statistical power. With this regard, it is therefore recommended 
that inclusion criteria should not be very conservative, and limited, for example, only 
to definite forms.54 Furthermore, as the latency period in MS, i.e., the period elapsing 
between the hypothesised exposure and first clinical manifestation, is long and 
extremely variable among individuals, the time of and residence at clinical onset 
might not be informative at all as to etiology or susceptibility.54 
Nevertheless, despite these potential limitations, we did find significant clustering 
patterns in our population, which points to the true presence of an infectious-like 
causative agent. Furthermore, such clustering was more marked when we controlled 
for gender, initial course, birth cohort and geographic sub-area. It is likely that some 
forms of Sardinian MS are triggered by infections.  
The observed-to-expected ratios in this study were relatively low, but it is difficult to 
judge what would represent a large effect in this type of analysis. This ratio is not 
comparable with normal values, as for example the odds ratio or relative risk that are 
based on individual data and not pairs of data. Further, the observed-to-expected 
ratios were rather similar along with age, due to the strong dependency between the 
analyses for each year. Only a few individuals included in the analysis were actually 
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migrating during childhood. Still, there was enough migration such that by the end of 
adolescence the ratio was reduced to 1.  
We cannot exclude the possibility that the clustering was caused by a confounding 
factor or by a factor(s) unrelated to the disease. However, a specific migration pattern 
in the general population being responsible for confounding is less likely because of 
the stability of the population. A rate-based cluster method might nevertheless have 
given more information on this issue. 
 5.1.4. Perceived health status and mild MS 
In Paper IV we showed that MS patients with no to mild disability according to 
EDSS score 3.5 rate their health status as poorer than the general population for all 
relevant health status domains except for bodily pain. This was true even for a 
subsample of MS patients with minimal disability in only one FS on EDSS (score 
2.0). Interestingly, despite patients’ low EDSS scores, physical functioning was 
rated especially poorly compared with the other subscales. These study results appear 
to be mainly confirmatory; however they have a specific interest, since coming from 
patients with absent/mild physical disability. 
Physical functioning and the role limitation due to physical health problems, i.e., the 
perception of problems in daily or occupational life as a result of poor physical 
health, were reduced among MS patients compared with the general population 
despite no or mild disability. Self-perceived general health, vitality and energy, fear 
of getting sick or for worsening of health, fatigue and tiredness were also worse in 
this subset of patients. Their emotional status interfered more with concentration, 
work productivity and other activities than among the general population. Physical 
and emotional health status had a greater impact on the quantity and quality of 
normal social activities compared with the general population in this group of 
nondisabled to mildly disabled MS patients. 
Further, this subset of MS patients also had lower scores than the general population 
in mental health status, although to lesser degree than for the other scales. Three of 
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the five questions included in this scale are related to depression and the lower score 
might indicate that also this group of patients has a slightly higher rate of depression 
than found in the general population. Fatigue and depression are generally highly 
frequent among MS patients and probably also affect the other domains of the health-
related quality of life.228 Fatigue might likely be an important component of self-rated 
poor physical functioning, which is not captured by the more objective disability 
measurement EDSS in mild MS. 
In accordance with other studies228,229 self-rated bodily pain in our patients did not 
differ from that of the general population and for both genders. Physical pain is not a 
common clinical feature of MS, with the exception of pain due to spasticity for EDSS 
scores higher than those used as inclusion criteria for the study. SF-36 bodily pain 
subscale has proved to be a reliable measure for painful chronic conditions, such as 
musculo-scheletal disorders and headache. Given the characteristics of pain in MS 
and the subscale dependence on physical scores, this subscale might not represent a 
suitable instrument for self-rating health status in these patients. 
In agreement with other studies228,230 the self-perceived health status among our 
patients did not depend on the number of years with the disease, nor the disease 
course significantly affected the patients’ self-rated health status. No differences were 
found between those receiving symptomatic treatment and those did not receive such 
treatment. 
Physical functioning was especially perceived worse among MS patients than among 
the general population, despite their fully ambulatory status on EDSS. This was true 
even for patients with minimal disability according to EDSS. Because the SF-36 
physical functioning subscale measures perceived daily ambulatory functioning, 
including climbing stairs and walking different distances, the low physical 
functioning subscale scores in this subset of patients conceptually disagreed with the 
EDSS definition of fully ambulatory. Such discrepancy was further corroborated by 
the weak statistical correlation (2.0%) found between the EDSS and the SF-36 
physical functioning subscale. This evidence raises uncertainty about EDSS 
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sensitivity in measuring physical impairment at this disease stage and indicates that 
the SF-36 physical functioning subscale is more sensitive. This is in accordance with 
other authors reporting on EDSS as an instrument to assess nervous system 
impairment but not overall mobility.157,231 Kurtzke’s EDSS sometimes considered 
“the gold standard” for disability scoring in MS,232-234 is observer-(usually 
neurologist-) rated and addresses impairment in its lower levels and mobility in the 
higher ones. The poor inter-rater reliability has lead people to suggest that it is 
necessary to see quite a large change on the scale (up to one entire point) to believe 
that the change is meaningful. As the EDSS is not a linear scale, patients spend more 
time at some levels than at others. This is the reason why a change of 0.5 EDSS 
points at a level of 5.5 or greater is as clinically important as a change of 1 EDSS 
point at level of 5.0 and below. Further, it is not clear whether EDSS short-term 
changes predict long-term disability.157  
On the other hand, as for SF-36 there is limited information on its application in MS, 
but there is some concern that it may not be specific enough for this condition, in that 
the physical functioning subscale has been shown to have reduced sensitivity when 
applied to patients with severe MS disability, due to marked floor effects.143,235 
Interestingly, by means of movement analysis technique, subclinical evidence of gait 
control dysfunction has been reported for MS patients with even “minimal disability 
in one functional system” (EDSS score of 0 to 2), who therefore had no objective 
walking restriction, signs of motor involvement or clinical spasticity.236  
The objective versus subjective measurement of physical functioning in MS may 
differ in the same patient. The patients may be able to catch their own impaired 
physical functioning at an earlier stage than neurologists objectively can. Nortvedt et 
al237 have shown that self-rated health can predict a change in MS disability measured 
using EDSS. In this study, high scores for the SF-36 general health subscale and the 
mental health subscale at baseline were correlated with decreased EDSS after 12 
months. The risk of worsening in EDSS after 1 year was two-fold among patients 
with poor or fair self-rated health status at baseline versus those rating their health as 
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good, very good or excellent. More objective measures such as EDSS itself had no 
predictive value at baseline. The authors concluded that self-rated health might partly 
reflect disease activity and thus represent a risk factor in the natural history of the 
disease. 
The meaningfulness of physical impairment on overall self-rated health status has 
been reported to differ between patients and evaluators (Rothwell et al, 1997).238 In 
this study, both clinicians and patients rated the impact of physical impairment 
differently compared with the general population and for the most relevant health 
domains. However, clinicians weighted the physical involvement of the disease more 
strongly on overall health status than patients did, whereas patients weighted their 
mental health and vitality as being more important than the clinicians did. The study 
included patients with moderate to severe disability (EDSS score ranged from 1 to 8).  
The SF-36 scores were compared in patients with benign MS (EDSS <3.5 at least 10 
years after disease onset), non-benign MS and normal controls in a population-based 
study conducted in western Norway.239 Patients with benign MS had a significantly 
better health status for all eight functional dimensions in the SF-36 compared with 
patients with non-benign MS. However, as compared to the normal population, they 
generally perceived a significantly poorer health status for all the dimensions in the 
SF-36 except for mental health. In addition, 25% of the benign MS patients had been 
awarded disability pension due to the disease itself. The definition of benign MS has 
been heavily weighted towards physical disability and in particular ambulation, but 
although meeting the criteria for a benign course, patients may be heavily disabled 
due to non-motor symptoms.  
Similar conclusions are drawn from our patient sample, in whom, despite the low 
disability score, the impact of the physical functioning on overall self-perceived 
health status was generally lower compared with the general population, especially 
for women. This evidence points to factors other than physical functioning playing a 
significant role in these patients’ self-perceived health status. 
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Our study on self-perceived health status presents some limitations. It did not 
comprise all MS patients living in the study area with the specific inclusion criterion 
of fully ambulatory status. Nevertheless, the hospital-based sample of consecutive 
MS patients, most of whom were undergoing immune prophylaxis and needed 
periodic follow-up visits at the Centre, was likely highly representative of a 
population of MS patients with low disability scores.  
Furthermore, cultural differences between Sardinians and mainland Italians160 might 
influence self-rated health status. Nevertheless, due to its cross-cultural validity, 
appropriateness and content comparability in tests on different Caucasian 
populations,240-242 the SF-36 was chosen to also avoid capturing the effect of such 
differences between the study and the reference population. Further, more than one 
third of the normative SF-36 data for Italy were collected from southern Italy,187 
where Sardinia is located. 
5.2. Implications for further research    
The evidences based on this work imply further investigations in two relevant areas 
of MS research in a population at high risk for the disease and characterised by 
peculiar socio-historical and ethnic features: the search for disease etiology, and the 
evaluation of the socio-economic burden in the disease early stages.      
The evidences stemming from Papers I-III point to the predominant role of 
exogenous factors in determining the disease and allow us to trace some of the most 
relevant features of such factor(s): (i) its concentration is particularly elevated in 
Sardinia as compared to other populations at similar ethnicity or latitude, (ii) its 
concentration is increasing over time and evenly across the study area, especially 
starting in the 1980s, (iii) its distribution may vary at microgeographic level (in rural 
versus urban sub-areas?) or the degree of its interaction with immuno-genetic features 
may be responsible for such spatial differences observed in the MS distribution (in 
close versus open communities?), (iv) exposure to such factor(s) is likely to occur in 
early childhood, (v) its concentration may regard the female more extensively than 
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the male population, (vi) the previous exposure of such factor should be 
predominantly searched in patients with RR MS, and (vii) it is probably not a 
causative agent with fixed-latency incubation period. However, it is worth to 
underline that such epidemiological characteristics were reported for subsets of 
patients which lends large support to the recently reappraised pathological 
heterogeneity of MS.243 As an example from our study, a smaller variation of age of 
onset was observed in patients showing space-time clustering as compared to non-
clustered patients. Even though our results in general are not compatible with a role 
of MS-specific infectious agents with fixed incubation period, it is possible that while 
clustered-patients reflect the occurrence of an infection, the non-clustered patients 
reflect a multiple heterogeneous nature of causative agents. 
On the basis of these clues, it will be possible to design analytical epidemiological 
studies. Ecological could be aimed at performing correlation analyses of the disease 
rate with one or more preferably quantified, or dichotomised, exposures distributed 
by space.199 These exposures could be environmental, e.g., measurable in air, water, 
or soil, socio-economic and demographic, e.g., income, social and occupational 
status, and lifestyle factors, e.g., smoking and diet, in relation to the spatially mapped 
disease. The obtained MS map could also be correlated with that of other diseases in 
Sardinia, if available. The correlation of MS with IDDM spatial mapping with MS 
can be very informative as to disclose common putative causative agents. MS and 
IDDM share predisposing HLA haplotypes,117-121 and have shown comparable 
epidemiological behaviour, with regards to increasing incidence and spatial 
clustering.122 
Based on the findings in Papers I-III and on the results from possible ecological 
studies, case-control studies could be performed. The study subjects should be 
assessed for the history of the occurrence of exposures (or events) of interest prior to 
disease onset and especially during childhood. This could be achieved through 
personal interviews or self-administered questionnaires with which a large number of 
risk factors could be investigated, including childhood infections and immunisation 
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history. Relatively to our findings, the following candidate exogenous factors need to 
be considered: EBV and infectious mononucleosis, CP, vaccinations, occupational 
exposures and environmental toxicants, sunlight and UV, climate, lifestyle factors, 
such as diet, macronutrients, saturated fat, linoleic caid, antioxidants, vitamin D, 
cigarette smoking, physical trauma, pregnancy, oral contraceptives and replacement 
therapies. Recent-onset patients (incident cases) and matched controls should 
preferably be included in the study so as to minimise inaccuracy in reporting 
exposures prior to disease onset or in childhood. Such studies could be conducted 
according to ad hoc guidelines established on the design itself, the questionnaire and 
database,244-246 and within a multicentre type of network.  
Disease surveillance, i.e., the systematic routine collection and analysis of health 
outcome data for disease control, can be extended to the adjacent provinces and 
possibly to the whole region.247 This could allow for a more sensitive a priori 
identification of clusters in space and time, and enable public health officials to 
conduct evaluations of situations that may be of public concern, other than the 
disease etiology itself. An on-going project on e-health supported by the Sardinian 
regional government will soon allow the surveillance of neurological disorders over 
the study area, by means of systematic computerised registry. 
Lastly, given the disease heterogeneity, efforts should be made to investigate 
exposures to risk factors by stratifying for clinical variables, like age of onset, type of 
initial onset and functional systems involved.   
With Paper IV we found that MS patients with no to mild disability on an objective 
measurement of disability rate their health status as being significantly worse than the 
general population does, and that this is especially true for self-rated physical 
functioning in both genders. Nevertheless, factors other than physical functioning 
contribute to the low scores for the other dimensions compared with the general 
population. These findings should encourage the implementation of strategies 
targeting a broad spectrum of health issues for MS patients starting in their early 
stage of the disease. In cost-of-illness studies they can provide clues to indicators to 
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socio-economic burden in the disease early stages, and elements for disease-specific 
interventions. 
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6. CONCLUSIONS 
Paper I 
Mapping the distribution of prevalence rates by commune of residence disclosed 
clustering patterns of MS at microgeographic level. In these sub-areas the disease 
prevalence is significantly higher than the provincial mean rate. Based on 1997 
prevalence, spatial clustering was found in the Sassarese sub-area, whereas based on 
prevalence rates by commune of residence in adolescence, the previous evidence was 
confirmed and also a tendency for spatial clustering was found in more interior 
communes (sub-areas 1, 3, 5). This microgeographic variation reflects the spatial 
distribution of disease risk factors. However, whether the nature of these factors is 
environmental or genetic, or due to interaction, is impossible to establish given the 
cross-sectional design of the study. 
Paper II 
Some heterogeneity in the distribution of incidence rates across sub-areas of the 
province of Sassari was found. However, regardless of such spatial distribution of 
incidence, rates steadily increased over time close to parallel in all sub-areas. Because 
such variation has occurred within a relatively short period of time, a corresponding 
change in the temporal distribution of an environmental etiological factor(s) in this 
genetically stable population must be assumed. The observed temporal change in the 
MS clinical phenotype with an increasing age at onset and a decreasing proportion of 
patients with progressive initial course, lends further support to this hypothesis. 
Paper III 
Space-time clustering patterns were found in our MS population, which strongly 
argues in favour of a common exposure to disease causative exogenous agents. Such 
clustering was found in early childhood, which is likely to be the age of disease 
induction of MS in Sardinia, at least for some subgroups of patients. The effect was 
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most evident in subsets of patients: women, in the most recent cohorts and in patients 
with RR course. This supports that the disease is heterogeneous and that 
etiopathogenetic variation may underlie clinical variation. Interestingly, the effect 
was found in sub-areas partially overlapping with those featuring tendency for spatial 
clustering in adolescence, which increases the probability for an exogenous factor to 
act in those areas. 
Paper IV 
MS patients with no to mild disability on EDSS rate their health status as being 
significantly worse than the general population does. This is especially true for self-
rated physical functioning among both women and men with MS. Nevertheless, 
factors other than physical functioning contribute to the low scores for the other 
dimensions compared with the general population. In nondisabled to mildly disabled 
MS patients, subjective scales aimed at rating physical functioning, such as SF-36 
though not disease specific, can detect subclinical physical disability and are thus 
more sensitive indicators. These findings should encourage the implementation of 
strategies targeting a broad spectrum of health issues for MS patients also in their 
early stage of the disease, and provide elements for disease-specific interventions. 
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Annexes 
I. Functional Systems and Expanded Disability Status Scale158 
Pyramidal Functions 
0. Normal. 
1. Abnormal signs without disability. 
2. Minimal disability. 
3. Mild or moderate paraparesis or hemiparesis; severe monoparesis. 
4. Marked paraparesis or hemiparesis; moderate quadriparesis; or monoplegia. 
5. Paraplegia, hemiplegia, or marked quadriparesis. 
6. Quadriplegia. 
V.  Unknown. 
 
Cerebellar Functions 
0. Normal. 
1. Abnormal signs without disability. 
2. Mild ataxia. 
3. Moderate truncal or limb ataxia. 
4. Severe ataxia, all limbs. 
5. Unable to perform coordinated movements due to ataxia. 
V.  Unknown. 
X.  Is used throughout after each number when weakness (grade 3 or more on pyramidal) 
interferes with testing. 
 
Brain Stem Functions 
0. Normal. 
1. Signs only. 
2. Moderate nystagmus or other mild disability. 
3. Severe nystagmus, marked extraocular weakness, or moderate disability of other 
cranial nerves. 
4. Marked dysarthria or other marked disability. 
5. Inability to swallow or speak. 
V.  Unknown. 
 
Sensory Functions  
0. Normal. 
1. Vibration or figure-writing decrease only, in one or two limbs. 
2. Mild decrease in touch or pain or position sense, and/or moderate decrease in vibration 
in one or two limbs; or vibratory (e.g., figure writing) decrease alone in three or four 
limbs. 
3. Moderate decrease in touch or pain or position sense, and/or essentially lost vibration 
in one or two limbs; or mild decrease in touch or pain and/or moderate decrease in all 
proprioceptive tests in three or four limbs. 
4. Marked decrease in touch or pain or loss of proprioception, alone or combined, in one 
or two limbs; or moderate decrease in touch or pain and/or severe proprioceptive 
decrease in more than two limbs. 
5. Loss (essentially) of sensation in one or two limbs; or moderate decrease in touch or 
pain and/or loss of proprioception for most of the body below the head. 
6. Sensation essentially lost below the head. 
V.  Unknown. 
 
Bowel and Bladder Functions 
0. Normal. 
1. Mild urinary hesitancy, urgency, or retention. 
2. Moderate hesitancy, urgency, retention of bowel or bladder, or rare urinary 
incontinence. 
3. Frequent urinary incontinence. 
4. In need of almost constant catheterization. 
5. Loss of bladder function. 
6. Loss of bowel and bladder function. 
V.  Unknown. 
 
Visual (or Optic) Functions 
0. Normal. 
1. Scotoma with visual acuity (corrected) better than 20/30. 
2. Worse eye with scotoma with maximal visual acuity (corrected) of 20/30 to 20/59. 
3. Worse eye with large scotoma, or moderate decrease in fields, but with maximal visual 
acuity (corrected) of 20/60 to 20/99. 
4. Worse eye with marked decrease of fields and maximal visual acuity (corrected) of 
20/100 to 20/200; grade 3 plus maximal acuity of better eye of 20/60 or less. 
5. Worse eye with maximal visual acuity (corrected) less than 20/200; grade 4 plus 
maximal acuity of better eye of 20/60 or less. 
6. Grade 5 plus maximal visual acuity of better eye of 20/60 or less. 
V.  Unknown. 
X.  Is added to grades 0 to 6 for presence of temporal pallor. 
 
Cerebral (or Mental) Functions 
0. Normal. 
1. Mood alteration only (does not affect DSS score). 
2. Mild decrease in mentation. 
3. Moderate decrease in mentation. 
4. Marked decrease in mentation (chronic brain syndrome-moderate) 
5. Dementia or chronic brain syndrome-severe or incompetent. 
V.  Unknown. 
 
Other Functions 
0. None. 
1. Any other neurologic findings attributed to MS (specify). 
V.  Unknown. 
 
Expanded Disability Status Scale (EDSS) 
0 Normal neurologic exam (all grade 0 in FS; Cerebral grade 1 acceptable). 
1.0 No disability, minimal signs in one FS (i.e., grade 1 excluding Cerebral grade 1). 
1.5 No disability minimal signs in more than one FS (more than one grade 1 excluding 
Cerebral grade 1). 
2.0 Minimal disability in one FS (one FS grade 2, others 0 or 1). 
2.5 Minimal disability in two FS (two FS grade 2, others 0 or 1). 
3.0 Moderate disability in one FS (one FS grade 3, others 0 or l), or mild disability in 
three or four FS (three/four FS grade 2, others 0 or 1) though fully ambulatory. 
3.5 Fully ambulatory but with moderate disability in one FS (one grade 3) and one or 
two FS grade 2; or two FS grade 3; or five FS grade 2 (others 0 or 1). 
4.0 Fully ambulatory without aid, self-sufficient, up and about some 12 hours a day 
despite relatively severe disability consisting of one FS grade 4 (others 0 or l), or 
combinations of lesser grades exceeding limits of previous steps. Able to walk 
without aid or rest some 500 meters. 
4.5 Fully ambulatory without aid, up and about much of the day, able to work a full 
day, may otherwise have some limitation of full activity or require minimal 
assistance; characterised by relatively severe disability, usually consisting of one 
FS grade 4 (others 0 or 1) or combinations of lesser grades exceeding limits of 
previous steps. Able to walk without aid or rest for some 300 meters. 
5.0 Ambulatory without aid or rest for about 200 meters; disability severe enough to 
impair full daily activities (eg, to work full day without special provisions). (Usual 
FS equivalents are one grade 5 alone, others 0 or 1; or combinations of lesser 
grades usually exceeding specifications for step 4.0.) 
5.5 Ambulatory without aid or rest for about 100 meters; disability severe enough to 
preclude full daily activities. (Usual FS equivalents are one grade 5 alone, others 0 
or 1; or combinations of lesser grades usually exceeding those for step 4.0.) 
6.0 Intermittent or unilateral constant assistance (cane, crutch, or brace) required to 
walk about 100 meters with or without resting. (Usual FS equivalents are 
combinations with more than two FS grade 3+) 
6.5 Constant bilateral assistance (canes, crutches, or braces) required to walk about 20 
meters without resting. (Usual FS equivalents are combinations with more than two 
FS grade 3+) 
7.0 Unable to walk beyond about 5 meters even with aid, essentially restricted to 
wheelchair; wheels self in standard wheelchair and transfers alone; up and about in 
w/c some 12 hours a day. (Usual FS equivalents are combinations with more than 
one FS grade 4+; very rarely, pyramidal grade 5 alone.) 
7.5 Unable to take more than a few steps; restricted to wheelchair; may need aid in 
transfer; wheels self but cannot carry on in standard wheelchair a full day; may 
require motorized wheelchair. (Usual FS equivalents are combinations with more 
than one FS grade 4+) 
8.0 Essentially restricted to bed or chair or perambulated in wheelchair, but may be out 
of bed itself much of the day; retains many self-care functions; generally has 
effective use of arms. (Usual FS equivalents are combinations, generally grade 4+ 
in several systems) 
8.5 Essentially restricted to bed much of the day; has some effective use of arm(s); 
retains some self-care functions. (Usual FS equivalents are combinations, generally 
4+ in several systems)  
9.0 Helpless bed patient; can communicate and eat. (Usual FS equivalents are 
combinations, mostly grade 4+) 
9.5 Totally helpless bed patient; unable to communicate effectively or eat/swallow. 
(Usual FS equivalents are combinations, almost all grade 4+) 
10 Death due to MS. 
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QUESTIONARIO SULLO STATO DI SALUTE SF-36
Data consegna I_I_I I_I_I I_I_I N° codice paziente I_I_I_I_I_I
ISTRUZIONI:  Questo  questionario  intende  valutare  cosa  Lei  pensa  della  Sua  salute.  Le
informazioni raccolte permetteranno di essere sempre aggiornati su come si sente e su come riesce a
svolgere le Sue attività consuete.
Risponda a ciascuna domanda del questionario indicando la Sua risposta come mostrato di volta in
volta. Se non si sente certo della risposta, effettui la scelta che comunque Le sembra migliore.
1. In generale, direbbe che la Sua salute è:
(Indichi un numero)
Eccellente ……………………………………………………………… 1
Molto buona …………………………………………………………… 2
Buona ………………………………………………………………….. 3
Passabile ……………………………………………………………….. 4
Scadente ………………………………………………………………... 5
2.  Rispetto ad un anno fa, come giudicherebbe, ora, la Sua salute in generale?
(Indichi un numero)
Decisamente migliore adesso rispetto ad un anno fa ………………..… 1
Un po’ migliore adesso rispetto ad un anno fa ...……………………… 2
Più o meno uguale rispetto ad un anno fa ……………………………... 3
Un po’ peggiore adesso rispetto ad un anno fa ………………………... 4
Decisamente peggiore adesso rispetto ad un anno fa ………………….. 5
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3. Le seguenti domande riguardano alcune attività che potrebbe svolgere nel corso di una qualsiasi
giornata. La Sua salute La limita attualmente nello svolgimento di queste attività?
(Indichi per ogni domanda il numero 1, 2, o 3)
SI, 
mi limita 
parecchio
SI, 
mi limita 
parzialmente
NO, 
non mi limita 
per nulla
a. Attività fisicamente impegnative, come correre,
sollevare oggetti pesanti, praticare sport faticosi
1 2 3
b. Attività  di  moderato  impegno  fisico,  come
spostare un tavolo, usare l’aspirapolvere, giocare
a bocce o fare un giretto in bicicletta 1 2 3
c. Sollevare o portare le borse della spesa 1 2 3
d. Salire qualche piano di scale 1 2 3
e. Salire un piano di scale 1 2 3
f. Piegarsi, inginocchiarsi o chinarsi 1 2 3
g. Camminare per un chilometro 1 2 3
h. Camminare per qualche centinaia di metri 1 2 3
i. Camminare per circa cento metri 1 2 3
l. Fare il bagno o vestirsi da soli 1 2 3
4. Nelle ultime 4 settimane  ,  ha riscontrato i  seguenti  problemi sul  lavoro o nelle altre attività
quotidiane, a causa della Sua salute fisica?
Risponda SI o NO a ciascuna domanda
(Indichi per ogni domanda il numero 1 o 2)
SI NO
a. Ha ridotto il tempo dedicato al lavoro o ad altre attività 1 2
b. Ha reso meno di quanto avrebbe voluto 1 2
c. Ha dovuto limitare alcuni tipi di lavoro o di altre attività 1 2
d. Ha avuto difficoltà nell’eseguire il lavoro o altre attività (ad esempio, ha
fatto più fatica) 1 2
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5. Nelle ultime 4 settimane, ha riscontrato i seguenti problemi sul lavoro o nelle altre attività,  a
causa del Suo stato emotivo (quale il sentirsi depresso o ansioso)?
Risponda SI o NO a ciascuna domanda
(Indichi per ogni domanda il numero 1 o 2)
SI NO
a. Ha ridotto il tempo dedicato al lavoro o ad altre attività 1 2
b. Ha reso meno di quanto avrebbe voluto 1 2
c. Ha avuto un calo di concentrazione sul lavoro o in altre attività 1 2
6. Nelle ultime 4 settimane,  in che misura la Sua salute fisica o il  Suoi  stato emotivo hanno
interferito con le normali attività sociali con la famiglia, gli amici, i vicini di casa, i gruppi di
cui fa parte?
(Indichi un numero)
Per nulla ..……………………………………………………………… 1
Leggermente …………………………………………………………… 2
Un po’ ………………………………………………………………….. 3
Molto ….……………………………………………………………….. 4
Moltissimo ……………………………………………………………... 5
7. Quanto dolore fisico ha provato nelle ultime 4 settimane?
(Indichi un numero)
Nessuno ...……………………………………………………………… 1
Molto lieve ..…………………………………………………………… 2
Lieve .………………………………………………………………….. 3
Moderato ….…………………………………………………………… 4
Forte …….……………………………………………………………... 5
Molto forte ……………………………………………………………... 6
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8. Nelle  ultime  4  settimane,  in  che  misura  il  dolore L’ha  ostacolata  nel  lavoro  che  svolge
abitualmente (sia in casa sia fuori casa)?
 (Indichi un numero)
Per nulla ..……………………………………………………………… 1
Molto poco ..…………………………………………………………… 2
Un po’ ………………………………………………………………….. 3
Molto …..….…………………………………………………………… 4
Moltissimo ……………………………………………………………... 5
9. Le seguenti domande si riferiscono a come si è sentito  nelle ultime 4 settimane. Risponda a
ciascuna domanda scegliendo la risposta che più si avvicina al Suo caso. Per quanto tempo
nelle ultime 4 settimane si è sentito…
(Indichi un numero per ogni domanda)
Sempre Quasi
sempre
Molto
tempo
Una parte
del tempo
Quasi 
mai
Mai
a. vivace brillante? 1 2 3 4 5 6
b. molto agitato? 1 2 3 4 5 6
c. così  giù  di  morale  che  niente  avrebbe
potuto tirarLa su? 1 2 3 4 5 6
d. calmo e sereno? 1 2 3 4 5 6
e. pieno di energia? 1 2 3 4 5 6
f. scoraggiato e triste? 1 2 3 4 5 6
g. sfinito? 1 2 3 4 5 6
h. felice? 1 2 3 4 5 6
i. stanco? 1 2 3 4 5 6
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10. Nelle ultime 4 settimane, per quanto tempo la  Sua salute fisica o il Suo stato emotivo hanno
interferito nelle Sue attività sociali, in famiglia, con gli amici?
(Indichi un numero)
Sempre .....……………………………………………………………… 1
Quasi sempre ...………………………………………………………… 2
Una parte del tempo …..……………………………………………….. 3
Quasi mai ..…………………………………………………………….. 4
Mai ……...……………………………………………………………... 5
11. Scelga la risposta che meglio descrive quanto siano VERE o FALSE le seguenti affermazioni.
(Indichi un numero per ogni affermazione)
Certamente
vero
In gran
parte vero
Non so In gran 
parte falso
Certamente
falso
a. Mi  pare  di  ammalarmi  un  po’  più
facilmente degli altri
1 2 3 4 5
b. La mia salute è come quella degli altri 1 2 3 4 5
c. Mi  aspetto  che  la  mia  salute  andrà
peggiorando 1 2 3 4 5
d. Godo di ottima salute 1 2 3 4 5
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